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ABBREVIATIONS 
AC adenylate cyclase 
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ER endoplasmic reticulum 
ERK extracellular signal-regulated kinase 
FA fluorescence anisotropy 
FBS foetal calf serum 
FCS fluorescence correlation spectroscopy 
FLIM fluorescence lifetime imaging microscopy 
FRET Förster/fluorescence resonance energy transfer 
G protein guanine nucleotide-binding protein 
GAP GTPase-activating protein 
GDP guanosine diphosphate 
GHSR growth hormone secretagogue receptor (named also ghrelin 
receptor) 
GPCRs  G protein-coupled receptors 
GTP guanosine triphosphate 
HTS high-throughput screening 
IP3 inositol 1,4,5-triphosphate 
Jak Janus kinase 
JNK c-Jun N-terminal kinase 
MAPK mitogen-activated protein kinase 
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MGRN1 mahogunin ring finger 1 (formerly known as mahoganoid) 
MITF microphthalmia-associated transcription factor 
MRAP melanocortin receptor accessory protein 
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PDE phosphodiesterase 
PKA protein kinase A 
PLC phospholipase C 
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POMC pro-opiomelanocortin 
RGS regulator of G protein signalling 
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SPA scintillation proximity assay 
STAT signal transducer and activator of transcription 
TR-FRET time-resolved-FRET 
VLP virus-like particle 
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INTRODUCTION 
Physiological processes in the human body are regulated by complex 
communication networks between cells – a wide variety of different signals are 
“recognised” and transmitted via receptors to provide certain effects and 
regulate certain functions. Diseases can be treated by addressing different 
receptors and influencing their functions. Members of one of the largest classes 
of cell-membrane receptors, so-called G protein-coupled receptors, play an 
important role in these regulatory processes. Thus, G protein-coupled receptors 
are of particular interest to drug developers/pharmaceutical companies as drug 
targets for the treatment of different diseases. Among nearly a thousand G 
protein-coupled receptors identified, the family of melanocortin receptors with 
five receptor subtypes is one of the most diverse in terms of physiological 
effects regulated. The developmental process of new drug discovery ranges 
from seeking, synthesis and ex vivo evaluation of pharmacological properties of 
biologically active molecules, to pre-clinical in vivo characterisation and finally 
clinical trials on humans. An assay in pharmacological research plays a very 
important role, as the ability to see the effect of the drug depends on the assay 
“eyes” through which it is monitored. The profile of drug actions can be very 
complex, so it is very important to understand the mechanism of receptor-ligand 
interaction. The main tools that would allow us to shed light on these 
mechanisms are: drug candidates and targets, assays providing experimental 
data concerning their interactions, and models describing interaction mecha-
nisms. Thus, the development of new methods, assay systems and model 
improvements would have an impact on all these components of the drug 
discovery process. 
The current thesis describes the progress of our studies of melanocortin 
receptors as drug targets starting from searching for drug candidates from a 
newly synthesised library of compounds, to the development of different new 
fluorescence anisotropy-based assay systems and new data analysis approaches. 
This allowed us to characterise the receptor-ligand interaction mechanisms in 
the melanocortin system, and enhanced the general understanding of the 
functioning of G protein-coupled receptors. 
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1. MELANOCORTIN RECEPTORS AS  
G PROTEIN-COUPLED RECEPTORS 
The family of melanocortin (MC) receptors consists of 5 members that belong 
to class A (rhodopsin/β2-adrenergic-like family) of the large superfamily of G 
protein-coupled receptors (GPCRs). GPCRs are cell surface receptors with 
sequence lengths ranging from about 300 to more than 3300 amino acid 
residues (Latek et al., 2012); they consist of seven -helical transmembrane 
domains that are interconnected by three alternating extra- and intracellular 
peptide loops; they provide signal transduction from outside the cell to a variety 
of downstream effector molecules inside the cell by catalysing the GDP/GTP 
(guanosine diphosphate/guanosine triphosphate) exchange on heterotrimeric G 
proteins (Gα-βγ). 948 genes encoding GPCRs have been identified from the 
human genome sequence (Takeda et al., 2002), which corresponds to about 5% 
of all human genes, but the deorphanisation or discovery of endogenous ligands 
for receptors is still in progress (Civelli et al., 2013). Due to their wide range of 
physiological functions regulated, GPCRs comprise the main target group for 
the treatment of different diseases. That is also why melanocortin receptors, and 
GPCRs in general, are of particular interest to drug developers/pharmaceutical 
companies as well as academic researchers.  
 
 
1.1. Melanocortin receptor subtypes 
Via activation or inhibition of the MC receptors a wide variety of different 
physiological effects can be regulated, the most well-known among them being 
skin pigmentation changes, anti-inflammatory and antipyretic actions, influence 
on sexual behaviour, food intake regulation, and influence on learning, attention 
and memory. 
The first two melanocortin receptor subtypes (MC1 and MC2) were cloned in 
the year 1992 by two independent groups (Mountjoy et al., 1992; Chhajlani and 
Wikberg, 1992), and to date five MC receptor subtypes (MC1-MC5) have been 
identified. MC receptors comprise high sequence homologies, ranging from 
67% identity between MC4 and MC5 receptors, to 42% between MC1 and MC2, 
and 38% homology between MC2 and MC4 receptors (Cone, 2000; Yang, 
2011). Phylogenetic analysis of the MC receptors’ family using full-length 
amino acid sequences of each receptor revealed that MC3, MC4 and MC5 
receptors are more closely related to each other than to the other two MC 
receptors (Schiöth et al., 2003a, 2005). MC receptors with about 300 amino acid 
residues in their sequences are one of the smallest GPCRs known. They share 
common structural characteristics like short N- and C- terminal ends and a very 
small second extracellular loop, and also conserved cysteine residues in their  
C-terminus, which may serve as sites for fatty acid acylation anchoring the  
C-terminus to the plasma membrane (Wikberg et al., 2000).  
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The human MC1 receptor is a 317-amino acid protein. It was first detected 
in malignant melanoma cells, but primarily MC1 receptors are expressed in 
melanocytes and involved in the regulation of pigment production. The 
activation of the MC1 receptors causes the formation of an increased proportion 
of black/brown eumelanin, whereas decreased activity results in the formation 
of a greater proportion of red/yellow phaeomelanin. The first MC1 receptor 
mediated effects were observed already in 1912 by Fuchs when he described a 
darkening of frog skin caused by a pituitary extract (Eberle, 1988); this can be 
considered as the beginning of history of melanocortin receptors and made a 
contribution to subsequent studies and the discovery of melanocortin hormones 
and their receptors. Subsequently the MC1 receptor has also been found to be 
expressed in immune/inflammatory cells (e.g. neutrophils, monocytes, 
macrophages), human dermal microvascular endothelial cells, Sertoli cells in 
the testes, and in the brain in neurons of the periaqueductal grey matter. 
Because of the wide distribution, in addition to pigmentation, the MC1 receptor 
has been shown to be involved in a number of other biological functions 
including anti-pyretic and anti-inflammatory actions (Wikberg et al. 2000; 
Abdel-Malek 2001), and regulation of pain and analgesia (Sandkühler, 1996; 
Mogil et al., 2003). 
The human MC2 receptor consists of 297 amino acids and it is expressed in 
the adrenal cortex zona reticularis and zona fasciculate, where it regulates the 
production of cortisol (Mountjoy et al., 1992). Besides the expression in the 
adrenal glands, the MC2 receptor has also been found to be expressed in skin 
(Slominski et al., 1996) and adipocytes (Boston and Cone, 1996). This receptor 
is unique among other MC receptors because it can be activated only by 
adrenocorticotropin (ACTH) and has no significant response to any other 
melanocyte-stimulating hormone (MSH) peptides. Additionally, in 2005 an 
accessory protein (named melanocortin-2 receptor accessory protein, MRAP) 
was identified that is required for functional expression of the MC2 receptor and 
critical for ACTH signalling (Metherell et al., 2005; Hinkle and Sebag, 2009).  
In 1993, two independent groups reported the cloning and characterisation of 
the rat (Roselli-Rehfuss et al., 1993) and human (Gantz et al., 1993a) MC3 
receptor genes. The human MC3 receptor is a 360-amino acid protein; it is 
predominantly expressed in the brain, but also in the peripheral nervous system, 
in the placenta, in several human gut tissues including the stomach, pancreas 
and duodenum, in the heart, in human monocytes, testis and ovary (Cone, 2000; 
Abdel-Malek, 2001). The MC3 receptor binds all melanocortins with similar 
affinity but is the only MC receptor to be activated by γ-MSH. The MC3 
receptor has been found to play a role in modulation of autonomic functions, 
energy homeostasis, feeding and inflammation, as well as appears to be 
involved in the regulation of sexual behaviour (Gantz and Fong, 2003; Catania 
et al., 2004; Wikberg et al., 2000; Martin and MacIntyre, 2004). 
The MC4 receptor was also cloned in 1993 (Gantz et al., 1993b) and it is a 
332-amino acid protein. It is widely expressed in the central nervous system, 
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including the cortex, thalamus, hypothalamus, brainstem, and spinal cord, but it 
is not found in the periphery (Wikberg et al., 2000; Abdel-Malek, 2001; Catania 
et al., 2004). It has been found to be involved in controlling food intake and 
energy expenditure, as well as pain sense, to exhibit anti-inflammatory effects, 
to increase systolic blood pressure, and to modulate erectile function and sexual 
behaviour (reviewed by Catania et al., 2004; Wikberg and Mutulis, 2008; 
Cooray and Clark, 2011), which have made it very interesting for many 
pharmaceutical companies. 
The 325-amino acid protein of the human MC5 receptor was cloned in 1993 
(Chhajlani et al., 1993) and it is the last of the MC receptor family receptors 
known to date. This receptor is ubiquitously expressed in peripheral tissues, 
including the adrenal glands, fat cells, kidney, liver, lung, lymph nodes, thymus, 
mammary glands, testis, ovary, stomach, skin, skeletal muscle and exocrine 
glands, such as lacrimal, sebaceous, prostate, seminal, pancreatic etc., and plays 
an important role in the production and/or secretion of the major products in 
these glands (Wikberg et al., 2000; Abdel-Malek, 2001; Catania et al., 2004). 
Expression of the MC5 receptor has also been detected in the brain and in  
B- and T- lymphocytes (Taylor and Namba, 2001), so it plays a role in immune 
regulation as well.  
 
 
1.2. Natural melanocortin receptor ligands 
The MC receptor system is unique among the other GPCRs in terms of having 
both naturally occurring activators and inhibitors. Two MC receptor 
antagonistic compounds, the agouti protein (also-called the agouti signalling 
protein, ASIP or ASP) and agouti-related protein (AGRP), are the only two 
endogenous antagonists of GPCRs identified to date (Lu et al., 1994; Ollmann 
et al., 1997; Catania, 2010).
1.2.1. Melanocortin receptor activators 
The melanocyte stimulating hormones (MSHs) were among the first biological 
peptides to be purified and sequenced in the 1950s (Cone, 2000). Extensive 
studies in subsequent years revealed that MC receptor specific ligands, also 
called melanocortins, are peptide hormones formed in post-translational 
processing of a common precursor protein named pro-opiomelanocortin 
(POMC). The full amino acid sequence of this protein was not known until the 
cloning of its cDNA in 1979 by Nakanishi and colleagues (Nakanishi et al., 
1979, when it became as the first example of a prohormone precursor encoding 
a variety of different neuropeptides and peptide hormones. Proteolytic cleavage 
of 241 amino acid polypeptide POMC generates α-, β-, and γ-melanocyte-
stimulating hormones (α-, β-, γ-MSH) and adrenocorticotropic hormone 
(ACTH; corticotropin) as well as opioid peptides, corticotrophin-like 
4
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intermediate lobe peptide (CLIP) and several other physiologically active 
peptides. Amino acid composition of these linear peptides can vary between 
different vertebrates but they all share the conserved tetrapeptide core sequence 
His-Phe-Arg-Trp in their structures, which is crucial for their biological 
activity. Melanocortins and their precursor POMC have been identified in the 
pituitary gland, the brain and various peripheral tissues of all classes of 
vertebrates. 
 
  ACTH Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-
Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-
Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH 
  α-MSH Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 
  β-MSH Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-
Pro-Lys-Asp-OH 
  γ1-MSH Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2 
  γ2-MSH Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly 
  γ3-MSH Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-Pro-Arg-
Asn(glycosyl)-Ser-Ser-Ala-Gly-Gly-Ser-Ala-Gln 
 δ-MSH Asp-Gly-Lys-Ile-Tyr-Lys-Met-Thr-His-Phe-Arg-Trp-NH2 
 
Figure 1. Amino acid sequences of natural melanocortin peptides.  
  
The sequence of ACTH for mammalian and non-mammalian vertebrates 
contains 39 amino acid residues (Fig. 1). For most of the mammalians region  
1–24 of the ACTH is identical, whereas region 25–39 remains highly variable. 
ACTH is the only natural activator for the MC2 receptor (Fig.2).  
The sequence of α-MSH contains the first 13 N-terminal amino acid 
residues of ACTH and it is almost identical in all species from which it has been 
isolated. The N-terminal serine residue of α-MSH is N-acetylated in many 
species and the C-terminal valine almost always contains a carboxamide group. 
These structure modifications guarantee stability of the α-MSH molecule 
against exopeptidases and increase the potency of the peptide (Abbott et al., 
2000). In addition to the abovementioned core tetrapeptide His-Phe-Arg-Trp 
also Tyr
2
 and Pro
12
 residues are common for α-MSH peptides in all species 
(Fig. 1). α-MSH is a nonselective agonist for melanocortin receptors MC1 and  
MC3-MC5 (Fig. 2). 
The -MSH peptide usually consists of 18 amino acid residues, but the 
structure of this peptide is more variable between different species; however, 
besides core tetrapeptide Tyr
5
 and Pro
15
 residues are also conserved (Fig. 1). 
γ-MSH peptides are endogenously present in three pharmacologically active 
forms named γ1-, γ2- and γ3- melanocyte-stimulating hormones (Fig. 1). γ1-MSH 
contains 11 amino acids and has an amidated C-terminal; γ2-MSH has 
additional Gly residue instead of an amidated C-terminal. γ3-MSH has an 
additional 11 C-terminal amino acid residues as it is formed by cleavage at the 
next dibasic amino acid cleavage site; in some species it may also contain  
15 
N-terminal Lys. Ȗ-MSH peptides have been detected in the pituitary and plasma, 
brain, vascular system, the bronchi and kidneys, however, in some vertebrate 
species Ȗ-MSH sequences have not been found in the structure of POMC (Cone, 
2000). Ȗ-MSH can be considered as an MC3 receptor specific activator as this 
receptor subtype is the only among other MC receptors with a higher binding 
affinity for Ȗ-MSH than other subtypes (Fig. 2). 
In the POMC structure of some cartilaginous fish like the dogfish, stingray, 
sharks and rays the sequence of į-MSH has been found, which is the most 
recently discovered melanocortin peptide (Dores et al., 2003). 
 
   Receptor subtype        Ligand affinity 
 MC1   D-MSH Ő E-MSH = ACTH !! Ȗ-MSH 
 MC2   ACTH 
 MC3    Ȗ-MSH = E-MSH = ACTH Ő D-MSH
 MC4   E-MSH Ő D-MSH = ACTH !! Ȗ-MSH 
 MC5    D-MSH Ő E-MSH = ACTH ! Ȗ-MSH 
 
Figure 2. Subtype selectivity of melanocortin peptides.  
 
Recent studies have revealed a new class of the MC receptor ligands ±  
E-defensins (Kaelin et al., 2008). 7KHȕ-defensins are a class of small, cationic 
proteins first recognised as antimicrobial components of the innate and adaptive 
LPPXQHV\VWHP0RUHUHFHQWO\LWKDVEHHQGLVFRYHUHGWKDWȕ-defensins function 
as MC1 and MC4 receptor ligands, capable of blocking the action of either 
VWLPXODWRU\Į-MSH or endogenous inhibitory ligands such as ASIP and AGRP 
(see next chapter 1.2.2. Melanocortin receptor inhibitors) (Nix et al., 2013; 
Beaumont et al., 2012), but some uncertainties still remain concerning  
ȕ-GHIHQVLQV¶biophysical and pharmacological basis of action. 
      
1.2.2. Melanocortin receptor inhibitors 
As mentioned previously, the melanocortin system is the only one known to 
date among other GPCRs to be regulated by endogenous ligands exhibiting not 
only agonistic but also antagonistic behaviour. The agouti protein (also-called 
agouti signalling protein, ASIP) and agouti-related protein (AGRP) are 
paracrine signalling molecules exhibiting antagonistic activity at the MC 
receptors (Lu et al., 1994; Ollmann et al., 1997). ASIP was cloned from the 
mouse in the early 1990s (Bultman et al., 1992; Miller et al., 1993). It was 
found that this protein acts in a paracrine manner to promote biosynthesis of 
red/yellow pheomelanin production over black/brown pigment eumelanin by 
affecting the MC1 receptor and antagonising the action of D-MSH. Expression 
of ASIP normally takes place in the skin, but its neuropeptide homolog AGRP 
is expressed in the arcuate nucleus of the hypothalamus, the subthalamic 
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region, and the adrenal cortex, and with slight expression in the lung and kidney 
(Gantz and Fong, 2003). AGRP is a potent orexigenic (appetite-stimulating) 
factor that acts as a competitive antagonist and blocks the action of the 
melanocortin agonists at the MC3 and MC4 receptors. On the other hand, an 
increasing number of GPCRs have been shown to exhibit basal/constitutive 
activity in vitro supporting the idea that a receptor can produce a signal without 
agonist intervention and that several antagonists can act as repressors of such 
spontaneous activity resulting in inverse agonism and negative efficacy (Chai et 
al., 2003; Coll, 2013). Several studies have demonstrated that in certain 
conditions the MC1 and MC4 receptors exhibit significant basal activity in the 
absence of -MSH, accordingly – AGRP acts as an inverse agonist at the MC4 
receptor (Haskell-Luevano and Monck, 2001; Nijenhuis et al., 2001) as well as 
ASIP may act as an inverse agonist at a constitutively active MC1 receptor 
(Siegrist et al., 1997). In summary, ASIP has a nanomolar affinity for the MC1, 
MC2 and MC4 receptors, a lower affinity for the MC3 receptor, but is not 
effective at the MC5 receptor, whereas AGRP has a nanomolar affinity for the 
MC3 and MC4 receptors and very little affinity for the MC1, MC2 and MC5 
receptors (MacNeil et al., 2002). However, the mechanism of molecular 
interactions between MC receptors and their antagonists is still not clear and 
requires additional investigation.  
To add to the complexity, perhaps the physiological relevance of melano-
cortin antagonists are even wider than commonly considered as it has been 
reported that AGRP is able to induce  arrestin-mediated endocytosis of the 
MC3 and MC4 receptors (Breit et al., 2006). If so, it can be hypothesised about 
the duality of the controlling role of this protein – probably AGRP possesses 
both rapid-acting, direct, ligand-receptor action and a slower-acting regulatory 
effect when the amount of the MC receptors located at the plasma membrane is 
temporarily reduced via endocytosis (Coll, 2013).  
Structurally both ASIP and AGRP are relatively small, easily diffusible 132 
residue glycoproteins with cysteine-rich C-terminal domains – within 40 amino 
acid residues of the C terminal, there are 10 cysteines, which form a network of 
five disulphide bonds. The cysteine-rich region contributes to the stability of 
these proteins, but also determines their subtype selectivity (Bures et al., 1998; 
McNulty et al., 2005; Chai et al., 2005). Moreover, both proteins contain a 
conserved tripeptide motif Arg-Phe-Phe in their cysteine-rich regions, which is 
closely related to the melanocortin core sequence and was proposed to be 
essential for binding to the MC receptors (Chai et al., 2005). 
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1.3. Accessory proteins in melanocortin system 
Growing evidence shows that GPCRs may interact with several accessory 
proteins in the cell – some of them are implicated in the correct folding and 
trafficking of the GPCRs to the cell surface, while others appear to participate 
in ligand binding or found to be associated throughout the life cycle of the 
receptor (Cooray and Clark, 2011). 
There are also several accessory proteins found in the melanocortin system, 
which are involved in the MC receptor function. In the 1960s spontaneous 
mutations gave rise to two mouse mutants known as mahogany and 
mahoganoid (Lane, 1960; Lane and Green, 1960; Phillips, 1963; Cooray 2011); 
subsequent studies led to the identification of corresponding proteins – 
mahogany (now known as attractin) and mahoganoid (now known as maho-
gunin or mahogunin ring finger 1; MGRN1). Similarities in the phenotypic 
characteristics of both mouse mutants (dark coat colour and lean body mass) led 
to the suggestion that attractin and MGRN1 may act as accessory proteins for 
both MC1 and MC4 receptor signalling (Cooray and Clark, 2011). Attractin 
encodes a type 1 transmembrane domain protein of 1428 amino acids with a 
large extracellular domain and a relatively short cytosolic tail of 128 amino 
acids. It was shown that attractin acts as a co-receptor for ASIP by assisting in 
the stability of the interaction between the C terminus of ASIP and MC1 
receptor. However, attractin does not bind to the AGRP and do not interact with 
the MC4 receptor (He at al. 2001). Subsequently Attractin-like protein (ALP) 
was discovered as interacting partner for MC4 receptor – it is a transmembrane 
domain protein consisting of 1371 amino acids and its cytosolic tail retains high 
sequence homology with attractin (Haqq et al., 2003). It was shown that specific 
regions of the C terminus of ALP interact with the C terminus of the MC4 
receptor suggesting that ALP acts as co-receptor for AGRP. However, it is still 
unclear whether ALP would interact with any of other MC receptors. 
Differently from attractin and ALP, mahogunin (MGRN1) encodes a ring 
domain-containing cytosolic E3 ubiquitin ligase (He et al., 2003) that is 
involved in regulation of energy balance and pigmentation via MC1 and MC4 
receptors. Different models have been suggested describing the action of 
MGRN1 (Phan et al., 2002), while recent studies revealed that mahogunin 
decreased MC receptor signalling by competing with Gs proteins to bind to the 
receptor-ligand complex (Perez-Olivia et al., 2009). Although it was shown that 
MGRN1 and MC2 receptors co-localise, more investigations are needed to 
clarify the possible involvement of MGRN1 in the function of the other three 
MC receptors (Cooray et al., 2011). 
To add complexity to an already complicated tale, syndecan-3 was identified 
as another co-receptor for melanocortin antagonists (Reizes et al., 2001; Bellin 
et al., 2002). Syndecan-3 is expressed in several hypothalamic nuclei that are 
known to play important roles in food intake and energy balance. It was shown 
that syndecan-3 binds AGRP and facilitates antagonism of -MSH activity at 
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the MC3/MC4 receptors, thus modulating feeding behaviour and energy balance 
(Bellin et al., 2002; Reizes et al., 2001). The syndecans are a family of heparan-
sulphate proteoglycans (HSPGs) that exist in a membrane-bound and a soluble, 
shedded form. Membrane-bound syndecans facilitate ligand-receptor inter-
actions and act as co-receptors being so involved in several physiological 
processes (Reizes et al., 2006). Cleaved from the cell surface however, they can 
inhibit that ligand-receptor interaction in a separate paracrine fashion.  
Recently, a family of novel melanocortin receptor accessory proteins 
(MRAPs) has been discovered (Metherell et al., 2005; Roy et al., 2007). 
MRAPs are small single transmembrane domain proteins and they act as MC 
receptor signalling modifiers (reviewed by Hinkle and Sebag, 2009; Webb and 
Clark, 2010). In humans they comprise two splice variants, MRAP and 
MRAP, and a second gene (orthologue), MRAP2 protein. MRAP encodes a 
protein of 172 amino acids, whilst MRAP encodes a protein of 102 amino 
acids. Both isoforms share identical N termini and transmembrane domains but 
differ at the C termini. MRAPs are beneficial for the MC2 receptor as they are 
required for trafficking of the MC2 receptor from endoplasmic reticulum (ER) 
to the cell surface and for receptor function in the adrenal cortex. Moreover, 
MRAPs are also essential for efficient MC2 receptor heterologous expression at 
the cell surface. However, they are not essential for the functional expression of 
other MC receptors – moreover, the MC1, MC3, MC4 and MC5 receptors suffer 
from the co-expression with MRAPs as they inhibit the efficacy of the MC 
receptors to stimulate cAMP (cyclic 3',5'-adenosine monophosphate) 
accumulation in response to melanocortin peptide binding (Chan et al., 2009; 
Sebag and Hinkle, 2009). MRAP2 was also found to assist MC2 receptor 
trafficking to the cell membrane; however it was not needed for the signalling 
of this receptor (Sebag and Hinkle, 2009). MRAPs are expressed in the brain as 
well as in the periphery but the mechanism of interactions with MC receptors is 
not fully clear at present (Cooray and Clark, 2011). 
 
 
1.4. Signal transduction 
The common signal transduction mechanism shared by the majority of GPCRs 
is the mediation of intracellular signalling through coupling to specific 
heterotrimeric guanine nucleotide-binding proteins (G proteins). Receptor-
activated G proteins are bound to the inside surface of the cell membrane and 
they consist of three subunits – the  subunit and a complex of tightly 
associated heterodimeric γ subunits (Hepler and Gilman, 1992). GPCRs act as 
guanine nucleotide exchange factors for the heterotrimeric G proteins. In the 
traditional view of heterotrimeric G protein activation the agonist binding to the 
receptor causes its activation by inducing conformational changes, which leads 
to the release of bound GDP from the associated G subunit and subsequent 
binding of GTP (Iiri et al., 1998). Binding of GTP to the  subunit induces 
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further conformational changes causing dissociation of the  subunit from the 
γ complex and from the receptor. Both the released GTP-bound Gα subunit as 
well as the Gβγ complex can then activate or inhibit a variety of downstream 
effectors and different signalling cascades (or second messenger pathways) in 
the cell (Neer, 1995). At least 27 distinct α subunits (including splice variants), 
5 β subunits and 14 γ subunits have been identified so far (Hepler and Gilman, 
1992; Downes and Gautam, 1999; Landry et al., 2006; Cabrera-Vera et al., 
2003) accounting for a vast variety of different combinations. The generally 
accepted G protein classification is based on the structural similarities of the Gα 
subunits and their mediated responses. According to this classification G 
proteins have been divided in four major subfamilies: Gαs family – stimulates 
the membrane-associated enzyme adenylate cyclase (AC) and activates the 
cAMP-dependent pathway by stimulating the production of cAMP from ATP 
(adenosine triphosphate); Gαi family – inhibits AC; Gαq family – increases 
intracellular Ca
2+
 concentration via stimulating membrane-bound enzyme 
phospholipase C (PLC); and Gα12 family – involved in regulation of Rho-
family guanine nucleotide-exchange factor signalling (so-called small or 
monomeric G proteins) (Landry and Gies, 2002; Elefsinioti et al., 2004). A 
comprehensive overview of effectors activated by various G-protein isoforms 
can be found in (Kristiansen, 2004; Landry et al., 2006; Birnbaumer, 2007).  
 
1.4.1. cAMP pathway 
It has been established that all melanocortin receptors are coupled with Gαs 
protein and accordingly act as AC activators. Activated AC catalyses the 
conversion of ATP into cyclic 3',5'-adenosine monophosphate (cAMP) leading 
to the increase of intracellular cAMP concentration. The cAMP is a small, 
diffusible molecule; it was discovered by Earl W. Sutherland and his colleague 
Theodore W. Rall and was the very first second messenger identified 
(Sutherland and Rall, 1958; Rall and Sutherland, 1958). As a second messenger, 
cAMP has a fundamental role in the generation of a wide variety of cellular 
responses by activating different effectors. The primary target of cAMP is the 
cAMP-dependent protein kinase A (PKA) that is a tetrameric complex of two 
catalytic and two regulatory subunits. cAMP activates PKA by binding to the 
regulatory subunits after which activated catalytic subunits are released from 
the complex. Catalytic subunits then modify the activities of a variety of target 
enzymes by phosphorylating them at the specific serine and threonine residues 
(catalytic subunit can even translocate to the cell nucleus where it 
phosphorylates the family of cAMP-response element binding protein (CREB) 
transcription factors). Thus, this pathway is involved in enzyme activation as 
well as regulation of gene expression – the activation of pre-existing enzymes is 
a much faster process in comparison with the regulation of gene expression, 
which can take even up to hours. Afterwards, the inherent GTPase activity of 
the Gs subunit slowly catalyses the hydrolysis of bound GTP to GDP, thereby 
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directly deactivating the Gs subunit and terminating its signalling (as well as 
terminating Gγ signalling through the re-association with the GDP-bound Gs 
subunit). Besides that, the signal of the pathway may also be terminated by 
other proteins – i.e. binding of RGS (family of regulators of G protein signalling 
proteins that serve as GTPase-activating proteins (GAPs)) to Gs subunit 
facilitates the hydrolysis of bound GTP to GDP. There is also evidence for 
direct interaction between RGS proteins and AC. The signalling can be also 
deactivated downstream by dephosphorylating the proteins phosphorylated by 
PKA, or the receptor can be desensitised (deactivated) (Sunahara and Taussig, 
2002; Ligeti et al., 2012). 
As an example, the control of skin pigmentation via the MC1 receptor is 
realised by the cAMP signal transduction pathway. The expression of POMC, 
production and secretion of MSH peptides in keratinocytes and subsequent 
increased expression of the MC1 receptors in melanocytes is induced by UV-
light exposure. Following agonist binding to the MC1 receptor in melanocytes 
causes activation of Gs/AC mediated elevation of intracellular cAMP, which 
in turn activates PKA. Upon its activation, PKA translocates to the nucleus 
where it phosphorylates the CREB family of transcription factors. 
Phosphorylated CREBs then induce the expression of genes containing CRE 
(cAMP-response elements) consensus sequences in their promoters, such as the 
transcription factor MITF (microphthalmia-associated transcription factor), 
which in turn activates genes producing the enzyme tyrosinase (TRP-1 and 
TRP-2), which are involved in melanogenesis by catalysing the synthesis of 
black/brown eumelanin from L-tyrosine, whereas inhibition of the MC1 receptor 
results in the synthesis of red/yellow phaeomelanin to a greater extent 
(Slominski et al., 2004).  
The multitude of different downstream effectors regulated (and accordingly 
a multitude of different functions regulated by MC receptors) arise after the 
elevation of cAMP and are primarily dictated by the individual melanocortin 
ligands, the receptor subtype and the tissue in which that receptor is expressed 
(Eves and Haycock, 2010). For example, -MSH acts as an anti-inflammatory 
and immunomodulatory agent via the MC1 and MC3 receptors in peripheral 
tissues and by the MC4 receptor in the CNS (Lasaga et al., 2008); this action is 
thought to be realised via the activation of the cAMP pathway and subsequent 
inhibition of NF-B, a transcription factor that exists in almost all cell types and 
plays a critical role in the immune system by regulating the expression of about 
150 genes, including several proinflammatory cytokines, cytokine receptors and 
adhesion molecules (Baeuerle and Henkel, 1994; Manna and Aggarwal, 1998). 
The discovery that melanocortins can control NF-B infers that any gene under 
the control of NF-B is under potential melanocortinic regulation. It is also 
reported that the activation of cAMP via the MC4 receptor is followed by 
phosphorylation of mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) or attenuation of p38 and JNK (c-Jun  
N-terminal kinase) MAPKs phosphorylation, which subsequently also results in 
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the inhibition of NF-B (Lasaga et al., 2008). However, although it has been 
shown that MAPKs participate in anti-inflammatory biology of -MSH, the 
exact mechanism still remains unclear.  
 
1.4.2. Alternative signalling pathways 
However, there is a growing number of reports suggesting that signalling 
pathways other than Gαs might contribute to the physiological effects of the MC 
receptors. For example, it has been shown that the MC4 receptor endogenously 
expressed in GT1-1 cells (immortalised hypothalamic neuronal cells) is able to 
activate the Gαq/PLC/Ca
2+
 pathway (Newman et al., 2006). Similarly, the data 
on human melanoma cells and keratinocytes suggest that although -MSH 
predominantly acts through Gαs/AC/cAMP pathway, but under conditions 
where this pathway was inhibited, Gαq mediated Ca
2+
 signalling came up 
instead. This suggests that in fact all five MC receptor subtypes would also be 
linked to the Gαq/PLC/Ca
2+
 signalling pathway (Elliott et al., 2004; Hoogduijn 
et al., 2002). There are also data available suggesting coupling of the MC4 
receptor to members of the Gαi/o family, thus strengthening the idea of dual 
coupling of the MC4 receptor to Gαs and Gαi/o proteins (Büch et al., 2009). 
Besides that, there are also data showing the connection of MC5 receptor 
signalling to the Jak/STAT pathway (Janus kinase/signal transducers and 
activators of transcription) probably via activation of the Gαq protein (Buggy, 
1998). Moreover, a new theory concerning a model where an agonist can induce 
different conformational changes of one particular receptor and each of 
conformations can be coupled with certain Gα protein subtype leading thus to 
the activation of different signalling pathways (also referred to as ligand-biased 
signalling) meets with approval on an example of the MC4 receptor – studies 
indicate that the MC4 receptor can couple to all three major classes of G 
proteins (Gαs, Gαi/o and Gαq) and can signal via different second messengers 
and activate different pathways (Yang, 2011). Moreover, it was shown that 
synthetic peptide and nonpeptide MC4 receptor agonists differ in their ability to 
induce different receptor conformational states and to couple the receptor to 
different G proteins (Yang, 2011).
This all together shows that the melanocortin system operates through very 
intertwining molecular mechanisms; however it should be kept in mind that 
cellular context, receptor expression level and alternate active receptor 
conformations all contribute to the data concerning MC receptor alternative G 
protein coupling and signalling (reviewed in Breit et al., 2011; Coll, 2013).  
 
Besides that, growing evidence indicates that many GPCRs are also able to 
transduce their signals through G protein independent pathways, e.g. via adapter 
proteins like arrestins, but not only (Woehler and Ponimaskin, 2009; Rajagopal 
et al., 2005; Shukla et al., 2011). Initially arrestins have been shown to 
terminate G protein-dependent signalling after agonist binding to the receptor; 
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however, arrestins may also activate cellular effectors like ERK-1/2 in a G 
protein independent manner (Shukla et al., 2011). As it has been shown that 
agonist binding to the MC4 receptor could mediate ERK-1/2 activation (Breit et 
al., 2011) and AGRP and -MSH induce interactions between MC4 receptor 
and arrestins (Breit et al., 2006), these effects probably contribute to G protein 
independent signalling. However, there are no clear data confirming MC 
receptor G protein independent signalling yet.    
 
 
1.5. Oligomerisation 
It is well reported and accepted that many GPCRs possess a common structural 
and functional feature to form homo- and heterodimers or even higher order 
oligomers (Bouvier, 2001; George et al., 2002; Milligan, 2009; Palczewski, 
2010). There are several suggestions but no clear answers concerning the 
functional significance and mechanism of receptor oligomer formation, as well 
as no direct evidence on where this process takes place and on its importance to 
cell surface expression (Terrillon and Bouvier, 2004). However, it has been 
proposed that one receptor molecule alone may not be sterically able to provide 
simultaneous interaction with all the heterotrimeric G protein subunits (Bulen-
ger et al., 2005). A detailed molecular mechanism needs to be elucidated, but 
continuously accumulating data suggest that there are many modulation or 
cross-talk possibilities between receptor subunits, as well as between the 
receptor and G proteins, and receptor and ligands. This indicates that organi-
sation of GPCR signalling appears to be more complex than conventionally 
proposed (reviewed by Rozenfeld and Devi, 2011).  
Numerous studies have shown that all MC receptors are also able to form 
oligomers. For example, MC4 receptors can form constitutive homodimers 
(Biebermann et al., 2003; Elsner et al., 2006; Nickolls and Maki, 2006; 
Kopanchuk et al., 2005, 2006; Chapman and Findlay, 2013), which exist in 
different dynamic conformational states depending on their association with the 
G protein and the agonist (Chapman and Findlay, 2013; Breit et al., 2011). 
Some data suggest that MC4 receptors can form even higher order oligomers 
(Chapman and Findlay, 2013). It has been shown that homodimerisation of the 
MC1 receptors occurs already before reaching the plasma membrane during 
their biosynthesis (Sanchez-Laorden et al., 2006; Zanna et al., 2008). Besides 
that, MC1 receptors form heterodimers with the MC3 receptor, while both of 
them can form homodimers as well (Mandrika et al., 2005). Additionally, 
accessory protein MRAP also plays a role in MC receptor oligomerisation and 
cell surface expression (Rodrigues et al., 2013). It was shown that although 
MRAP does not influence MC2 receptor homodimer formation, but it is required 
for their cell membrane expression, as in the absence of MRAP MC2 receptor 
homodimers were retained in the ER (Sebag and Hinkle, 2009). On the 
contrary, MRAP was found to inhibit MC4 and MC5 receptor cell surface 
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localisation, and disrupted MC5 receptor dimer formation (Sebag and Hinkle, 
2009; Chan et al., 2009). Moreover, recently it was found that hypothalamic 
GPCRs involved in body weight maintenance and regulation of food intake 
interact with each other via the heterodimer formation. For example, MC3 
receptor heterodimerises with the ghrelin receptor (also known as the growth 
hormone secretagogue receptor, GHSR) resulting in a modulation of functions 
of both receptors, whereas the MC4 receptor forms heterodimers with G protein-
coupled receptor 7 (GPR7) (Rediger et al., 2009, 2012).  
It is supposed that cross-talk between both, homomer and heteromer, re-
ceptor subunits may be characterised by some level of co-operativity within the 
complex, where binding of a single ligand to one monomer can change pro-
perties of the other (Biebermann et al., 2003; Kopanchuk et al., 2005. 2006; 
Rediger et al., 2012; Chapman and Findlay, 2013). Thus, understanding the 
physiological role of oligomer formation between different types of GPCRs and 
identification of regulatory mechanisms of these homo- and heteromers may be 
a prerequisite for highly specific drug development via discrete sets of 
signalling effectors (a phenomenon termed “heteromer-directed signalling 
specificity” (Rozenfeld and Devi, 2011).  
 
 
1.6. Melanocortin receptor active  
synthetic compounds 
The development of novel and selective peptic agonists and antagonists for MC 
receptors has closely followed the identification of various MC receptor 
subtypes. These receptors participate in regulation of a vast variety of different 
physiological functions, including, energy balance and feeding behaviours 
(obesity, anorexia), pigmentation, sexual behaviour (erectile dysfunction, sexual 
motivation), temperature control, pain and inflammatory and immune 
responses. There is a need for potent, biologically stable, certain MC receptor 
subtype selective ligands, both agonists and antagonists, that would have or 
have not, if desired, the ability to cross the blood-brain barrier. This explains 
why MC receptors and their ligands have become objects of interest for much 
research both from academic and industrial laboratories.  
As native MSH peptides are biologically unstable, being easily hydrolysed 
by proteases and easily oxidised, the first attempts towards new MC receptor 
active synthetic compounds were related with modifications of the core 
sequence and stabilisation of natural MSH peptides. Introduction of the 
pseudoisosteric amino acid norleucine (Nle) into position 4 of α-MSH prevents 
oxidation of methionine (Met
4
). Enzymatic stability could be increased by 
replacing phenylalanine at the position 7 (Phe
7
) with unnatural DPhe
7
. The 
resulting α-MSH peptide analogue [Nle4, DPhe7]-α-MSH (shortly, NDP-α-MSH 
or named also melanotan-I (MT-I); Fig. 3) was the first synthetic superpotent 
and stable agonistic peptide for all the MSH-binding melanocortin receptors 
24 
(MC1,3–5) with highly prolonged biological activity (Sawyer et al., 1980). 
Radiolabelled derivatives of NDP-α-MSH have been extensively used for 
studies of biological functions of the MC receptor both in vitro and in vivo. 
Subsequent modifications in the melanocortin “advanced” core tetrapeptide 
sequence His-DPhe-Arg-Trp on the basis of computational studies and 
extensive structure-activity relationship (SAR) studies (Hruby et al., 1984) led 
to the discovery of melanotan-II (MT-II; Ac-Nle
4
, c[Asp
5
, DPhe
7
, Lys
10
]-α-
MSH[4-10]-NH2; Fig. 3), which is a truncated cyclic lactam analogue of α-
MSH. MT-II has even higher agonistic potency on all the MSH-binding MC 
receptors (MC1,3–5) than NDP-α-MSH. It possesses high in vivo stability and 
prolonged activity, and it can cross the blood-brain barrier (Al-Obeidi et al., 
1989; Hadley et al., 1989). 
Subsequent studies by using the MT-II cyclic template as a starting point led 
to the discovery of the first potent synthetic antagonists for MC receptors 
(Hruby et al., 1995). Minimal changes in the structure of MT-II by substitution 
of only one amino acid (DPhe
7
 with more bulky aromatic naphthylalanine 
DNal(2’)7) resulted in a compound named SHU9119 (or [DNal(2’)7]-MT-II; 
Fig. 3) with a completely different bioactivity profile – it demonstrates potent 
and selective antagonistic activity for MC3 and MC4 receptors, but also acts as a 
partial agonist at the MC1 and MC5 receptors. 
Seeking for subtype selectivity led to the one of the first subtype selective 
agonists found MS05 (Fig. 3), which is a peptide ligand possessing more than 
1200-fold higher affinity for the MC1 receptor over all other MC receptor 
subtypes (Szardenings et al., 2000). It has been proposed for usage as an anti-
inflammatory agent. 
Another MC4 receptor-specific antagonist, HS131 (Schiöth et al., 2003b), 
has an 18-fold preference for the MC4 receptor over the MC3 receptor and 290- 
and 410-fold over the MC1 and MC5 receptors, respectively. 
 
NDP-α-MSH Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH2 
MT-II Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 
MS05 Ser-Ser-Ile-Ile-Ser-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 
SHU9119 Ac-Nle-c[Asp-His-DNal(2’)-Arg-Trp-Lys]-NH2 
HS131 Ac-c[Cys-Gly-DNal(2’)-Arg-Trp-Cys]-NH2 
 
Figure 3. Structures of synthetic melanocortin peptides. 
 
In spite of the remarkable success towards improvement of biological properties 
of native melanocortins, generally, peptides are regarded to be unsuitable for 
drug development due to their low enzymatic stability, poor oral bioavailability 
and high cost of production. However, other than per oral drug administration 
possibilities can be applied for synthetic peptide drugs, e.g. injections, 
intranasal administration, subcutaneous drug delivery, etc., can be used. As an 
example, PT-141 (now named as Bremelanotide) (Molinoff et al., 2003) is an 
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activator of the MC1 and MC4 receptors introduced by Palatin Technologies. 
However, intranasal drug administration for the treatment of male and female 
sexual dysfunction was discontinued due to arisen side effects of increased 
blood pressure. Nevertheless, at the moment new clinical trials of this com-
pound are in progress (human Phase 2B studies) by using a new subcutaneous 
drug delivery system that appears to have less effect on blood pressure (Palatin 
Technologies, 2013). To obtain substances suited for medical use there is an 
interest in highly selective non-peptide compounds imitating the most important 
structural features of the natural melanocortins. Early studies led to the 
assumption that the -turn structure of melanocortins’ core region provides a 
conformation essential for biological activity (Hruby et al., 1984). Since then, a 
wide variety of different scaffolds connected with side-chains containing 
structurally different pharmacophoric groups has been examined to mimic the 
“biologically active” spatial conformation of melanocortins. For example, 
extremely simple scaffolds, such as tertiary amides (Mutulis et al., 2007), or 
quite complicated tri-substituted nine-membered heterocycles (Haskell-Luevano 
et al., 1999) correspond to this spatial conformation and have been used to 
generate libraries of synthetic MC receptor active ligands. The majority of small 
molecule non-peptide and peptoid melanocortin agonists introduced by different 
pharmaceutical companies are derivatives of piperidines or piperazines (Pfizer, 
Amgen, Bristol-Myers Squibb, Eli Lilly, Merck, Neurocrine, Taisho, Procter 
and Gamble) or substituted guanidines (Chiron, Melacure) (Bednarek and Fong, 
2004; Wikberg and Mutulis, 2008). These compounds have been proposed 
(some of them have undergone different phases of human clinical trials as well) 
for the treatment of obesity and/or erectile dysfunction as well as for treatment 
of anxiety and depression (reviewed by Wikberg and Mutulis, 2008; Boughton 
and Murphy, 2013; King et al., 2007). As an example, THIQ (Fig. 4), highly 
potent and selective MC4 receptor agonist, is a small molecule piperidine 
derivative discovered by Merck research group (Sebhat et al., 2002). THIQ has 
been studied in detail in rat models and shown to increase erectile activity 
(Martin et al., 2002), but no human trials have been performed. However, this 
ligand and its radioactive analogue (Mutulis et al., 2003) have been used in 
scientific research – in studies of the MC4 receptor ligand binding mechanism 
(Kopanchuk et al., 2006) and signalling mechanism (Cai et al., 2004). Results 
suggested that non-peptide and peptide agonist ligands have different ligand 
binding as well as signalling mechanisms. 
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Figure 4. Structure of selective MC4 receptor agonist THIQ (N-[(3R)-1,2,3,4-
tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-
(1H-1,2,4-triazol-1-ylmethyl) piperidin-1-yl]-2-oxoethylamine) and its radiolabelled 
analogue [
125
I]THIQ.   
 
Along with a greater understanding of the complexity of the melanocortin 
receptor system, over the past decade or so it has become widely appreciated 
that melanocortin receptors possess functional allosteric binding sites. Allosteric 
modulators bind receptor domains topographically distinct from the orthosteric 
ligand binding site (binding site on a receptor for the native ligand), altering the 
biological activity of the orthosteric ligand by changing its binding affinity, 
functional efficacy, or both. For example, set of ligands that are allosteric 
activators and inhibitors of the melanocortin receptors has been identified on the 
basis of modelling the conformation of MT-II (Cain et al., 2006). Allosteric 
ligands may provide additional possibilities for regulation of receptor functions 
as they not only affect receptor’s orthosteric ligand binding site, but can also 
modulate signalling pathways (Hruby et al., 2011; Yang, 2011).    
Multivalent ligands (multimeric analogues of naturally occurring ligands) 
that simultaneously bind to multiple receptors can be used for obtaining 
enhanced specificity and higher affinity in comparison with corresponding 
monovalent ligands due to multivalent interactions via statistical and/or 
cooperative effects on binding. Melanoma is a type of skin cancer that develops 
in melanocytes, and MC1 receptor is known to be overexpressed at the 
melanoma cell surface. Therefore, targeting receptor overexpression via the use 
of multivalent interactions provides an alternative way to enhance selectivity 
toward these cancer cells (Brabez et al., 2013; Hruby and Cai, 2013). 
Furthermore, bivalent and heterobivalent ligands that interact with receptor 
homo- or heterodimers, respectively, could be highly specific and effective tool 
for specific modulation of receptor signalling capacity – as an example, for 
patients suffering from obesity or cachexia, targeting of homo- and/or 
heterodimerised MC3, MC4 and GHSRs could represent a valuable tool to 
modulate food intake (Rediger et al., 2009; 2012). Similarly, feasibility of 
heterobivalent targeting approach has been shown on tumour cells expressing 
MC1 and cholecystokinin-2 receptors (CCK2R) and with synthetic ligands that 
contain both, MSH and cholecystokinin pharmacophores (Xu et al., 2012). 
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Radiolabeled heterobivalent peptidic ligands have been proposed to be a 
valuable tool for in vivo imaging and therapy of malignant diseases (Fischer et 
al., 2013). 
Although much has been learned from the various structure-activity 
relationship studies of the MC ligands since of the first studies regarding MC 
system, it still remains difficult to design ligands de novo with specific activities 
at specific MC receptors. However, seeking new ligands has helped to improve 
the general understanding about the functioning of the MC system and about 
different opportunities to treat diseases and to maintain human health (Irani et 
al., 2004; Holder and Haskell-Luevano, 2004; Hruby et al., 2011; Yang, 2011). 
In fact, melanocortin ligands with multiple unique biological activities have led 
to clinical trials for pigmentation, melanoma, feeding behaviour, and sexual 
behaviour and function (Hruby and Cai, 2013; Boughon and Murphy, 2013). 
For example, Rhythm, a biotechnology company developing peptide 
therapeutics, in September 2013 announced the initiation of the first of a series 
of clinical trials with RM-493, the company’s novel MC4 receptor small-peptide 
agonist, for the treatment of obesity in individuals with a genetic deficiency in 
the MC4 receptor pathway (Rhythm Pharmaceuticals, 2013).  
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2. METHODS FOR G PROTEIN-COUPLED 
RECEPTOR STUDIES 
GPCRs can be studied from different points of view, by using different 
strategies and methods, but among the most used ones are assays assessing the 
receptor-ligand binding affinity (ligand binding assays) and efficacy (functional 
assays). Ligand bound GPCRs are activated to change the conformation and 
transduce an extracellular signal into the cell. The majority of GPCRs are 
normally present at very low concentrations in native tissues. That is why 
highly sensitive methods are required for their detection and characterisation. 
 
 
2.1. Ligand binding assays 
Receptor-ligand binding assays can be used to characterise receptor and its 
ligands’ interactions, giving parameters of intrinsic affinity of ligands to the 
receptor, association/dissociation rates, and the density of receptor in tissues, 
cells or receptor preparations. 
 
2.1.1. Radioligand binding 
Radioligand binding was implemented as a method for the detection of 
receptors in 1965 by Paton and Rang (Paton and Rang, 1965). Shortly after that 
this method was also used in melanocortin system studies, where binding of 
125
I-labelled ACTH to its adrenal binding sites was demonstrated (Lefkowitz et 
al., 1970a, 1970b, 1970c). The high sensitivity and selectivity of the method 
allowed for performing experiments in preparations from native tissues as well 
as transfected cells thus becoming conventional or so-called “classical” method 
for molecular pharmacology. This method also allows for characterisation of 
properties of nonradioactive compounds by their ability to displace the binding 
of a radiolabelled molecule to the receptor (orthosteric agonists/antagonists) or 
to modulate the affinity of a radiolabelled ligand for the binding to the receptor 
(some allosteric modulators). It has made this method indispensable for a long 
time for the discovery of new drugs targeting specific receptors (Chen et al., 
2012). 
In this method the receptor-bound radioligand and free radioligand are 
separated by filtration through glass fibre filters, gel-filtration columns or by 
centrifugation. The first radioactive MC peptides were 
125
I-, 
3
H-, 
14
C-, or 
35
S-
labelled ACTH and α-MSH. The low specific radioactivity of 14C (63 
mCi/mmol per atom) in spite of its long half-life (5760 years) restricts its use in 
ligand binding assays. Tritium 
3
H (specific radioactivity = 29.6 Ci/mmol per 
atom and half-life = 12.26 years) suits well for receptor binding assays and also 
for physiological experiments, but the relatively high price of ligands’ 3H 
labelling limits its usage. 
35
S has a much higher specific radioactivity than 
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tritium (1500 Ci/mmol per atom), but also a much shorter half-life of only 87.2 
days. It would be an ideal label for radioligands, but usually there are no direct 
ways to insert 
35
S into structure of compounds of interest. 
125
I has a specific 
radioactivity of about 2200 Ci/mmol per atom but comparatively short half-life 
of 60 days, which demands that radioligand should be used within 5–6 weeks 
after preparation. In spite of this limitation 
125
I is the most frequently used label 
for peptide ligands as it can be relatively easily introduced in peptide molecules. 
The most frequently used radioligand for characterisation of the MC receptors is 
[
125
I]-NDP-α-MSH (Eberle, 1988).  
Although the radioligand binding method is powerful and still frequently 
used, it also has several limitations, such as heterogeneity, which requires an 
additional separation step for the bound and unbound ligand and causes 
nonequilibrium in the system. Moreover, a lot of important information 
concerning ligand binding mechanism could be lost during this cumbersome 
separation step when rapid reactions and/or weak receptor/ligand complexes are 
investigated. Besides that, safety, waste and cost problems associated with 
radioactive ligands also must be kept in mind. 
  
Another radioisotopic technique, scintillation proximity assay (SPA), makes it 
possible to use radioisotopes for monitoring binding reactions continuously in 
homogeneous conditions without the need to separate free from bound 
components (Udenfriend et al., 1987; Glickman et al., 2008; Berry et al., 2012). 
This technology exploits “SPA beads” or scintillating fluomicrospheres into 
which scintillant is incorporated. Besides that, “SPA beads” are functionalised 
with affinity tags in order to bind GPCRs, for instance. If a radioalabelled tracer 
molecule is bound to the receptor in close proximity of the fluomicrosphere 
(depending on isotope used, the distance from 1 to 125 m), energy transfer 
occurs by photons being given off from the radioactive molecule; it stimulates 
the scintillant to emit light, which can then be detected. Since the development 
of SPA technology it has been essentially improved (including miniaturisation 
and automation) and has become a powerful tool for high-throughput screening 
(HTS) (reviewed by Glickman et al., 2008). However, the main problem in 
using SPA technology for HTS of GPCR ligands is demand of high-quality 
receptor preparations in large enough quantities for immobilisation purposes. 
Typically, either recombinantly expressed whole cells or purified cell 
membranes are used along with “SPA beads”. Thus, issues like signal-to-noise 
ratio, signal stability, relatively high costs of production of “SPA beds” as well 
as hazards and restrictions concerning exploitation of radioisotopes still are 
important reasons for developing alternative homogeneous, non-radioactive 
methods.  
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2.1.2. Fluorescence methods 
Fluorescently labelled ligands are being used increasingly as an alternative to 
radiolabelled ligands allowing monitoring and visualisation of ligand binding to 
the receptor (and other interactions/events with participation of fluorescently 
labelled partners) in living cells. Novel fluorescent probes stand out with high 
molecular brightness, low photon-bleaching and insensitivity to solvent polarity 
and pH changes. These qualities have contributed to the development of a set of 
alternative methods to radioligand binding assays that exploit different intrinsic 
fluorescence aspects/properties of the fluorophore (intensity, wavelength, life-
time, anisotropy). These parameters can be measured independently or in 
combination, thus providing more detailed information about certain interaction 
processes studied. Moreover, fluorescence measurements possess a very high 
sensitivity, providing the opportunity to observe biological mechanisms on a 
molecular level. Thus the versatility of fluorescence phenomena can be 
exploited for GPCR studies both in bulk solution and in the single molecule 
level. Fluorescence techniques are compatible with live cell experiments, 
making these advantageous over radioligand binding assays. Fluorescent 
ligands have been used for GPCR studies ranging from microscopic detection of 
receptor localisation in tissues and cells and demonstration of the ligand-bound 
receptor internalisation, to spectroscopic ligand binding assays and to 
sophisticated studies of receptor interaction mechanisms with different partners 
(ligands, other receptors, G proteins, etc.). Among ligand binding methods, 
fluorescence polarisation-based fluorescence anisotropy (FA), Förster/ 
fluorescence resonance energy transfer (FRET) and time-resolved-FRET (TR-
FRET), fluorescence correlation spectroscopy-based assays (FCS) and others 
have found wider recognition and applications in GPCR studies (Chen et al., 
2012; Sridharan et al., 2014). Each fluorescence technique has several 
advantages, as well as certain limitations. 
 
2.1.2.1. Fluorescence anisotropy 
The fluorescence anisotropy (FA) method is based on the phenomenon that the 
population of fluorescent probes emits light with a certain degree of polarisation 
when excited by plane polarised light. The fluorescence lifetime refers to the 
average time the molecule stays in its excited state before emitting a photon. 
Thus, the polarisation extent of emitted light of fluorophore activated by 
polarised light depends on pluorophore’s freedom of movement within its 
lifetime. The binding of fluorescent ligands to bigger and more massive 
receptor proteins constrains their freedom of movement resulting in a greater 
extent of polarisation of the emitted fluorescence. Emitted fluorescence changes 
can be detected as a change in emitted fluorescence intensities parallel (I||) and 
perpendicular (I) to the plane of excitation plane, respectively, and used for 
calculation of FA signal. Changes in FA signal can be followed in real-time 
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without of any separation step requirement. FA signal at time t after the 
initiation of the binding reaction can be defined as parameter      and 
calculated as following: 
   
      
           
            
 (1) 
 
Thus, a simple principle, homogenous system and possibility of continuous on-
line monitoring of the receptor-ligand interaction dynamics, as well as moderate 
requirements for equipment makes the polarisation-based FA assay quite 
attractive for the assessment of GPCR-ligand binding properties. Although 
several small-molecule fluorescent ligands for GPCRs are available (Vernall et 
al., 2013), in general, peptide ligands are rather suited for labelling with 
fluorescent probes than small-molecule compounds as conjugation with 
fluorophore more probably does not affect the biological properties of the 
peptide. It has been shown that NDP-α-MSH also retains its activity after 
labelling with fluorescent dyes (Prystay et al., 2001; Do et al., 2006; Nosjean et 
al., 2006; Nicholson et al., 2006; Veiksina et al., 2010, 2014) However, 
although the FA method looks very promising, it still has not been widely 
adopted in fundamental receptor-ligand binding interaction studies as well as 
for screening a wide range of receptors from different sources. Some of the 
obstacles affecting an assay’s signal-to-noise ratio are the availability of 
suitable fluorophore-coupled ligands and receptor preparations with sufficiently 
high receptor concentration. As this method is ratiometric, changes in the FA 
signal can be detected only if the ratio of bound and free fluorescent ligand 
portions is altered (Nosjean et al., 2006). It means that concentrations of 
receptor and ligand used have to be comparable. It is different from classical 
radioligand assays, where the used ligand concentration is much higher than 
receptor concentration ([L]   [R]) and reactions are carried out under pseudo 
first-order conditions). In other words, in FA assays reactions are performed 
under second-order conditions ([L] ≈ [R]), where ligand depletion has to be 
taken into account thus adding to the complexity of data analysis (Roehrl et al., 
2004; Veiksina et al., 2014). Moreover, if the total emission intensity (expressed 
as      ) changes during the binding reaction (reflects the changes of 
fluorophore’s quantum yield), the data analysis becomes even more compli-
cated (Jameson and Mocz, 2005). 
 
2.1.2.2. Other fluorescence techniques 
The sensitivity of fluorophore’s fluorescent properties from changes in its 
environment opens other opportunities for assessment of binding of a 
fluorescently-tagged ligand to the receptor. Thus, ligand binding can be assayed 
by determination of changes in fluorescence emission spectrum (wavelength) or 
intensity (quantum yield) upon the binding process. As fluorescence intensity is 
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linearly dependent on the number of fluorophores in a sample, it provides a 
basis for quantitative measurements. Binding can be measured in a solution 
containing receptors (maintained in a homogeneous suspension) and a ligand 
without the need to separate the bound from free ligand. This approach relies on 
the ability to distinguish specific binding-dependent fluorescence changes from 
fluorescent background contributions arising from unbound ligand, cellular 
autofluorescence and non-specifically bound ligand (Sridharan et al., 2014). 
 
In 1948 Theodor Förster first described the molecular process of energy transfer 
between two molecules (Förster, 1948). This approach, fluorescence/ Förster 
resonance energy transfer (FRET) between two fluorophores, where the 
emission from one overlaps the excitation of the other can be used for 
monitoring of ligand binding to a receptor. Usually two proper fluorophores are 
used, where one is coupled with a ligand and the second with a receptor. There 
is strong distance dependence for resonance energy transfer to occur. By donor 
and acceptor molecules coming into close enough proximity, FRET can be 
detected either via enhancement of the acceptor fluorophore’s fluorescence 
emission (with a longer wavelength) or via loss of emission from the donor 
fluorophore (with a shorter wavelength). In the latter case, even the non-
fluorescent acceptor can be used. The assay is carried out in a “mix and 
measure” format without the separation requirement of bound and unbound 
ligands. This allows for determination of ligand binding kinetics, but the FRET 
approach can also be used for assessment of receptor oligomerisation, ligand-
dependent conformational changes in GPCRs, as well as in functional receptor 
activity assays. The main limitations of these FRET-based assays are related to 
the availability of good FRET donor/acceptor pairs, labelling of GPCRs and 
ligands without the loss of their properties and expression of tagged-receptors in 
cells. Moreover, frequently there is a very low signal-to-noise ratio because the 
fluorescence emission wavelengths of many organic molecules and the cell 
culture medium overlap those of the common FRET donors. The influence from 
photobleaching, crosstalk (direct excitation of the acceptor by the wavelength of 
light used to excite the donor) and bleedthrough (overlap of the donor and 
acceptor emission spectra) have to be taken into account, which may con-
siderably complicate the interpretation of FRET signal (Chen et al., 2012; 
Zhang and Xie, 2012; Goddard and Watts, 2012; Sridharan et al., 2014).  
Some of these issues can be eliminated and better sensitivity can be achieved 
by using the time-resolved mode of FRET measurements (TR-FRET). Here, 
unique properties of lanthanides like a long-lived excited state (up to milli-
second range), large Stokes’ shift between absorption and emission maximums 
and narrow emission peak can be utilised by using lanthanide-containing FRET 
donors. Thus, several orders of magnitude longer fluorescence lifetime of donor 
molecule over the non-specific background fluorescence enables the specific 
signal to be measured after a defined delay period when the background 
fluorescence has already diminished (Chen et al., 2012; Zhang and Xie, 2012; 
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Goddard and Watts, 2012). Commonly used lanthanides in this type of assays 
are europium (Eu), terbium (Tb), samarium (Sm) and dysprosium (Dy). 
Lanthanide-labelled melanocortin ligands (like Eu-labelled NDP--MSH) have 
been used in studies of the MC receptors within the TR-fluorescence approach 
(Handl et al., 2004) and for new multivalent MC receptor ligand evaluation for 
treatment of melanoma (Brabez et al., 2013). However, challenges concerning 
synthesis of lanthanide-labelled ligands have also been shown (Alleti et al., 
2013). 
 
Fluorescence lifetime changes also can be exploited in receptor-ligand binding 
studies. Fluorescence lifetimes for commonly used fluorophores usually are in 
the nanosecond range. Measuring the fluorescence intensity with time 
resolution below 10
–9
 seconds (modulated excitation) gives access to fluoro-
phore lifetimes. These measurements can be performed in two ways – under 
frequency domain or under time domain (Turconi et al., 2001). The lifetime is 
characteristic for a fluorophore and depends on its local environment, thus 
allowing monitoring of interactions of molecules or changes in the immediate 
surroundings of the fluorophore. Fluorescence lifetime measurements can be 
applied for studies of interactions in solution as well as in single molecule level 
(fluorescence lifetime imaging microscopy, FLIM). However, the most 
common use of this technique is the determination of FRET – because in the 
presence of FRET the donor molecule has an additional pathway over which it 
can de-excite, its lifetime is shortened and this effect can be measured. The 
advantage of FLIM compared with conventional FRET is that its signal is more 
sensitive and precise since it is independent of the fluorescence intensity and 
artefacts due to scattering and absorption within the sample. In FLIM the 
fluorescence signal can be recorded with high temporal and spatial resolution 
allowing its application in combination with other fluorescence techniques and 
thus giving access to a wider range of physical parameters that make 
interpretation of results more detailed, easier and more reliable (Liu et al., 
2008).  
 
Fluorescence correlation spectroscopy (FCS) is based on detection of changes 
in a fluorescent ligand’s spatial mobility. Time-dependent fluorescence 
emission fluctuations are measured from a small illuminated volume (confocal 
volume) during diffusion of fluorescently labelled molecules within this 
volume. Autocorrelation analysis of the fluctuations in fluorescence intensity 
provides information about the diffusion time and number of fluorescent 
molecules in the observation volume. In this way, processes can be accessed on 
the single molecule level, but at the same time many single events are 
statistically evaluated via the correlation function. Thus, FCS provides the 
ability for simultaneous tracking of free and bound ligand populations in the 
same solution (without the need for physical separation of these ligand 
fractions) and for measuring of ligand binding in a time-dependent manner with 
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single-molecule sensitivity (Briddon and Hill, 2007; Jakobs et al., 2012; 
Sridharan et al., 2014). The most common parameters extracted from FCS are 
the diffusion coefficient and the concentration of fluorescent particles in the 
observation volume, which allow quantification of ligand-receptor interactions 
by estimation of receptor-bound ligand fraction. Besides that, it allows for 
assessment of the localisation of receptors within the cell and in different 
membrane domains, as well as the aggregation state of the receptors. It may 
provide us with information about the activation and signal transduction 
mechanisms; furthermore, as receptors reside in their natural environment, 
results are more likely to represent physiologically relevant interactions (Liu et 
al., 2008). Moreover, FCS with fluorescence-tagged receptors can also be used 
for detection of receptor oligomers and for determination of receptor monomers 
in an oligomeric complex (Herrick-Davis and Mazurkiewicz, 2012). Recently, 
FCS extension with two-focus and dual-colour detection mode opened new 
possibilities for in vivo detection of receptor-ligand interactions (Ries et al., 
2009).  
There has been remarkable progress made in the last years in field of single 
molecule detection methods based on the fluorescence (Hell, 2009). The single 
molecule assays permit detection of events often masked in averaged ensemble 
measurements as they allow for simultaneous detection of different molecular 
components from many single molecule reactions occurring in parallel in a bulk 
solution. For example, single-molecule microscopy studies using fluorescent 
ligands have shown dynamic dimerisation of M1 muscarinic and N-formyl 
peptide receptors (Hern et al., 2010; Kasai et al., 2011). Fast-developing instru-
mentation possibilities allow for new techniques to become more available to a 
wider range of scientists. Furthermore, due to the small volume of the sample 
needed and the short time required for sample measurement, single molecule 
assays have the potential for miniaturisation and HTS (Christensen et al., 2013). 
These considerations would make single molecule multiparameter assays 
(simultaneous collection and integration of intensity, anisotropy, lifetime, 
FRET, etc., data) favourable from future perspectives as wide variety of pro-
cesses, including dynamic binding and conformational dynamics of proteins, 
could be studied (Kudryavtsev et al., 2007; Felekyan et al., 2012).  
 
 
2.2. Functional assays 
Upon ligand binding, GPCRs change their conformation and activate coupled G 
proteins, which subsequently promote second messenger production via 
downstream effectors. Although ligand binding assays can provide us with 
information about binding affinity and in some cases about binding kinetics 
and/or oligomerisation, they do not tell us whether the compound is an agonist 
or an antagonist, or allow assessment of the overall physiological potency of the 
compound. Functional assays are aimed to assess receptor activation and 
35 
signalling by measuring either G protein activation or G protein mediated 
events (including second messenger generation and reporter gene transcription 
in response to receptor activation). Since GPCR signalling consists of a series of 
spatial and temporal events, an important consideration is whether to measure a 
proximal or distal signalling step after GPCR stimulation. Measurement of 
events proximal to receptor activation will reduce the incidence of false 
positives. However, moving down the signal transduction cascade will enhance 
the signal-to-noise ratio due to signal amplification (Zhang and Xie, 2012), but 
from the other hand it also increases the possibility of non-selective or 
overlapped signal detection as many GPCRs may activate multiple signalling 
pathways (Denis et al., 2012). 
 
2.2.1. cAMP assay 
All the MC receptors are considered to be coupled with Gs protein and 
signalling via second messenger cAMP. Conventional cAMP assays measure 
changes in intracellular cAMP levels after stimulation or inhibition of cAMP 
production. Gs protein-coupled receptors positively stimulate the activity of 
AC, thus increased cellular cAMP levels can be measured straightforward, 
whereas it is more challenging to test compounds (especially antagonists) for 
Gi/o protein-coupled receptors because of the requirement pre-stimulate AC 
with forskolin (Zhang and Xie, 2012). Additionally, since the intracellular 
cAMP concentration is regulated by the balance between the production rate by 
ACs and degradation rate by phosphodiesterases (PDE), an inhibitor of PDE 
(e.g. 3-isobutyl-1-methylxanthine; IBMX) might be required in the system 
during assay performance. However, despite the seemingly simple detection of 
the Gs protein’s activation, one should be careful as an almost 10-fold 
abundance of the Gαo protein (member of Gαi family) over Gαs protein has been 
shown in cells possibly leading to hindered Gαs-signalling in heterologous 
systems (Landry et al., 2006). Usually, levels of cellular cAMP are measured in 
a competition assay with labelled cAMP, where they both compete for binding 
to an anti-cAMP antibody or cAMP binding protein (Nordstedt and Fredholm, 
1990). Radioactive isotope-labelled cAMP is still frequently used in con-
ventional ligand-binding and SPA assay formats. Several commercial 
fluorescence-based assays for cAMP detection are available as well – e.g. based 
on fluorescence polarisation, TR-fluorescence, etc., approaches (Zhang and Xie, 
2012; Chen et al., 2012; Denis et al., 2012). Moreover, FRET and BRET 
(bioluminescence resonance energy transfer) biosensor-based assays have been 
developed for real-time detection of intracellular cAMP accumulation or 
turnover in live cells. Biosensor-based approaches rely on the use of genetically 
encoded fluorescent reporters using cAMP binding properties of cAMP 
downstream effectors, PKA and Epac (exchange proteins directly activated by 
cAMP). This non-lytic, live-cell assay format is based on the conformational 
changes of the biosensor upon cAMP binding and subsequent FRET signal 
36 
changes. High sensitivity of biosensor-based assays allows also the detection of 
Gi-coupled receptor active compounds without an artificial forskolin 
stimulation (Zhang and Xie, 2012; Chen et al., 2012). This type of functional 
assay has also been applied for detection of the MC4 receptor allosteric 
modulators (Pantel et al., 2011), as well as for studies of the Ca
2+
 and Mg
2+
 
influence on ligand binding to MC1 receptor endogenously expressed in B16F10 
murine melanoma cells (Mazina et al., 2012).  
Additionally to “conventional” signalling, the phenomenon of ligand-biased 
signalling has been observed for MC receptors, as well (see section 1.4.2. 
Alternative signalling pathways). As ligand-biased signalling implies that a 
single receptor has pleiotropic signalling properties and crosstalk of signalling 
pathways may occur at different levels downstream from the receptor, it 
becomes challenging to evaluate functional activities of certain ligands and 
receptors. A lot of effort has been made during the last decades to find strategies 
that would overcome challenges concerning biased ligands (Denis et al., 2012); 
however, it still remains to be solved. 
 
2.2.2. Other assays 
An early cellular process after ligand binding to the GPCR is G protein 
activation, which results in the exchange of a guanine nucleotide and the 
dissociation of the G subunit from the G protein complex. Thus, another type 
of functional assays (popularly known as GTPγS binding assays) directly 
measure the guanine nucleotide exchange, which is not subjected to ampli-
fication or regulation by other cellular processes (Milligan, 2003). Shortly, these 
assays employ nonhydrolysable GTP analogues (e.g. [
35S]GTPγS (from here the 
unofficial name) or non-radioactive, europium-labelled GTP-Eu) and measure 
their agonist-dependent accumulation. Typically assays are performed on the 
plasma membranes prepared from cells expressing GPCRs of interest. The 
GTPγS binding assays allow for distinguishing full or partial agonists from 
neutral antagonists, inverse agonists, and allosteric regulators (Harrison and 
Traynor, 2003; Zhang and Xie, 2012).  
The assessment of Gq (but also Gi) protein activation can be realised via 
different assays that measure activities of downstream effectors and/or gene-
ration of second messengers. As an example, in response to Gq protein 
activation and subsequent PLC activation, second messenger inositol 1,4,5-
triphosphate (IP3) is produced in cytoplasm. IP3 then binds to IP3 receptors in 
ER thus inducing transient Ca
2+
 efflux from the internal stores to the cytoplasm. 
Both, radiometric (filtration and SPA assays) and fluorescence-based (including 
biosensor systems), assay formats are used to measure concentrations of 
intracellular Ca
2+
 or inositole phosphates (IP3/IP1) reflecting to PLC activity 
(Denis et al., 2012; Chen et al., 2012; Zhang and Xie, 2012). Due to the 
complexity and transient nature of calcium signalling sometimes it would be 
difficult to properly quantify experimental data in order to avoid misinter-
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pretation of pharmacology of novel receptor ligands (Charlton and Vauquelin, 
2010). A number of studies have also shown MC receptors providing their 
effects via Gαq/PLC/Ca
2+
 pathway (see section 1.4.2. Alternative signalling 
pathways).  
Reporter-gene assays are another alternative for detecting GPCR activity. 
Activation of GPCRs downstream may lead to initiation of the expression of 
genes via responsive elements for second messengers like CRE (cAMP-
response element) and others. The transcription of a reporter gene is initiated by 
a transcription factor binding to its designated promoter region; e.g. CRE 
promoter is activated as downstream effect of the Gs/AC/cAMP pathway. As 
this assay observes events downstream from second messenger production, it 
may even take several hours to allow transcription of the reporter gene (Hill et 
al., 2001). For example, melanogenesis in melanocytes is realised by the MC1 
receptor’s activated Gs/AC/cAMP signal transduction cascade, and subsequent 
CRE activation which leads to expression of genes and activation of enzymes 
involved in dark pigment eumelanin production (Slominski et al., 2004). 
Commonly used reporter-gene assays use reporter-enzymes with activities 
linked to a variety of colorimetric, fluorescent or luminescent readouts, such as 
luciferase, -galactosidase, -lactamase and others (Zhang and Xie, 2012). The 
first colorimetric assay applied in MC receptor studies utilised a β-galactosidase 
(lacZ) gene fused to the CRE for assessment of the MC5 receptor activation 
(Chen et al., 1995). 
Besides the abovementioned other possibilities for evaluation of GPCR 
activation exist. To mention only some of them – fluorescence-based imaging 
assays for monitoring -arrestin recruitment or receptor trafficking (events 
involved in receptor desensitisation); or even label-free, whole cell assay 
technologies presenting different strategy in measuring signal transduction 
(integrated or cumulative responses are detected rather than the resolution of 
individual events) and employing biosensors that convert the summation of 
ligand-induced changes to optical, electrical, calorimetric, acoustic, magnetic or 
other quantifiable signals (Chen et al., 2012; Zhang and Xie, 2012).  
 
 
2.3. GPCR preparations in assay systems  
GPCRs can be studied from different aspects and with the aid of a wide variety 
of different methods and instrumentations. Depending on the study aims, the 
chosen analysis method, signal outputs and other considerations, GPCR can be 
studied on different receptor sources starting from live organisms to purified 
engineered GPCR proteins reconstituted into artificial membranes (Lundstrom, 
2013). From a pharmaceutical point of view the main challenge for new drug 
discovery is to detect, characterise and optimise the biological activity of active 
molecules found. Depending on the assay used one is able to see some certain 
effects of the compound and/or receptor studied through the “eyes” of the assay, 
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whereas the type of receptor source used determines which (or the absence of 
which) signal will be found and in which extent. These aspects should be kept 
in mind when experimental results are interpreted and a signal-producing event 
is characterised.  
Historically ligand-induced events have been studied on isolated tissues 
(organs) and whole-animal assays. For example, the first melanocortin receptor 
mediated effects were observed in 1912 on frog’s skin when pituitary extract 
caused its darkening (Eberle, 1988). Such types of assays have their own 
specific applications and character, but one of the advantages is that these 
assays can be conducted in real time and with receptor systems in a natural 
environment. Usually tissues isolated from non-human sources are used; 
however, some differences in drug activity in human and animal tissues may 
exist. A shortcoming of isolated tissues is that they are not compatible with 
high-throughput assays where a large number of compounds should be tested. 
Besides that, from tissue experiments we can get only an overall drug effect, but 
the mechanism of drug action cannot be studied. Further technological progress 
and development of radioligand binding assays (Paton and Rang, 1965), and 
implementation of receptor sources form recombinant cell lines from human 
and other species (whole cells or cell membrane preparations) provided 
increased assays’ throughput and assay miniaturisation possibilities.  
As most of the GPCRs are normally present at relatively low concentrations 
in native tissues, very sensitive methods are required for their detection, or 
receptors from overexpressed or concentrated preparations have to be used. 
There are a wide range of methods and expression systems available for the 
heterologous production of recombinant GPCRs and other membrane proteins. 
Choosing a receptor model system is an essential question, since all of them 
have their own characteristics as well as advantages and disadvantages for 
applicability. Traditionally, binding studies have been conducted by employing 
mammalian cells – both transient and stable cell lines. Mammalian cells provide 
the most sophisticated protein processing (proper protein folding and post-
translational modifications when compared to other expression systems), but the 
glycosylation profile may vary to a great extent between different mammalian 
cell types (Hossler et al., 2009). The expression levels from mammalian cell 
lines are considered to be relatively low; however, improvements in this area 
have been achieved (Geisse and Fux, 2009).  
Higher expression levels (with lower costs of maintenance) can be achieved 
with insect cell lines. Although glycosylation in insect cells is similar but not 
identical to that in mammalian cells (Katoh and Tiemeyer, 2013), the 
posttranslational processing machinery in many aspects is very similar to 
mammalian cells, which allow for producing highly authentic end products of 
mammalian origins (Makela and Oker-Blom, 2008). Besides that, efforts have 
also been achieved in new insect cell line generation with a “mammalianised” 
protein glycosylation pathway (Aumiller et al., 2012). Insect cells are one of the 
most widely used expression systems for structural and ligand-binding studies, 
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but functional responses can also be studied on co-expressed cells (Masuda et 
al., 2003; Sakihama et al., 2008; Mitsui et al., 2012). We have used membrane 
preparations from baculovirus infected Sf9 cells (insect cells isolated from the 
pupal ovarian tissue of the fall armyworm Spodoptera frugiperda) in FA-based 
assay for characterisation of the dynamics of ligand binding to MC4 receptors 
(Veiksina et al., 2010). Insect cells are essentially free from endogenous 
GPCRs, which make them valuable for studies on orphan GPCRs and receptor 
dimerisation. Moreover, as the baculovirus/insect cell system allows simul-
taneous co-expression of multiple proteins of interest, it provides the possibility 
to engineer cells for studying a certain process with a particular emphasis and 
under an improved signal-to-noise ratio (Schneider and Seifert, 2010).   
Besides that, it has been shown that membrane proteins expressed on the 
surface of Sf9 cells also bud with baculoviruses and remain on their surface 
(Loisel et al., 1997). Thus, budded baculoviruses (BBV) represent more or less 
a “one size fits all” solution – viruses that are used for the delivery of genetic 
information into the cells and for the expression of receptors are also used for 
the exposure of those receptors on their own surfaces and can be used as a 
source of GPCRs (for more details see Box 1 in Results and Discussion part). 
Additionally, baculovirus vectors with mammalian cell-active cassette can be 
used in the so-called BacMam system for functional GPCR, signalling, reporter 
and other protein expression in mammalian cells (Kost et al., 2005; Davenport 
et al., 2009; Mazina et al., 2012). Virus vectors from another, alphavirus family 
(typically, the Semliki Forest virus, SFV) can also be used for recombinant 
expression of GPCRs in mammalian cells, which allow for achieving very high 
expression levels and can be adapted to large-scale production (Hassaine et al., 
2006). The SFV/mammalian cell system also allows co-expression of multiple 
targets simultaneously (Lundstrom, 2003).  
Bacterial- and yeast-based GPCR production has been utilised quite a lot as 
well, but generally these systems are considered to be less adequate platforms 
(especially for membrane proteins) due to decreased likelihood of proteins’ 
proper folding and posttranslational modifications (Lundstrom, 2013).  
Besides that, different artificial GPCR sources (including cell-free expres-
sion systems) have found acceptance in a variety of continuously developing 
specific new applications for receptor studies on the molecular level. For 
example, for structural and functional studies of GPCRs and other membrane 
proteins, they may be solubilised in the presence of detergent from their parent 
systems, purified and then reconstituted into artificial hydrophobic membrane 
systems like different types of lipoparticles, micelles or nanodiscs (Klammt et 
al., 2007; Junge et al., 2011). However, the proper folding and functionality of 
reconstituted membrane proteins remains challenging issue within these 
methodologies since different naturally present essential components could be 
eliminated. Porous beads (Roizard et al., 2011), “blebbing” structures or (sub-
)micrometre sized cell derived vesicles (Grasso et al., 2013) and surface-
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immobilised proteins (Früh et al., 2010) are only a few of the recently deve-
loped, interesting and “advanced” carriers of GPCRs.  
Basically, introduction of radioligand binding assays pushed the “traditions” 
of GPCR research from whole-system kinetic approaches towards reductionist, 
non-natural recombinant system approaches with simplified read-outs (Kenakin, 
2009). However, now, when very sensitive and versatile analysis methods are 
available, again more integrated approaches can be applied for studies of 
systems in a complex instead of studies of isolated system components. 
Considering the complexity of GPCR signalling machinery (including different 
receptor conformations, allosteric modulators, biased signalling, cell type-
related functional selectivity, interactions with other signalling proteins like -
arrestins as well as scaffolding proteins) the main shortcoming of recombinant 
systems would be related to the absence of the whole complex of components 
required for characteristic therapeutic phenotypes. This could be overcome by 
the implementation of versatile multiparameter assay systems with cells 
containing a full complex of signalling reactants and monitoring signalling 
events as much as possible. To mention only a few, simultaneous detection of 
several Ca
2+
-dependent signalling events (Piljic and Schultz, 2008), or 
simultaneous detection of spatially colocalised changes in Ca
2+
, cAMP and 
PKA activities (Woehler, 2013). From the future perspective, multiparameter 
assay systems could be considered advantageous since a more likely response 
will be detected, including “hidden” efficacies in addition to considered 
“primary” activity (discussed in Hynes et al., 2013). Low expression level of 
GPCRs in primary cells (human or from transgenic animals with disease 
phenotype) are no longer an obstacle for highly sensitive, single cell, real-time, 
label-free detection systems that would provide clinically/therapeutically more 
relevant functional results. However, a considerable increase in the complexity 
of “resolving” these signals precludes these technologies from becoming trivial 
and commonly available to a wide range of scientists (Kenakin, 2009; 
Lundstrom, 2013).  
Assay costs, simple performance, quickly obtainable results and highly 
qualified personnel are only a few of the aspects addressed when an assay 
system and receptor sources are chosen for solving certain scientific questions. 
Thus, any tools that allow for solving the enormous complexity of GPCRs’ 
machinery (even in extremely small steps) have their own right to existence. 
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3. AIMS/OBJECTIVES OF THE STUDY 
Since melanocortin receptors are involved in the regulation of a wide variety of 
physiological functions, melanocortin ligands have remarkable therapeutic 
potential for the treatment of several human disorders. Thus, it is very important 
to understand the mechanisms of receptor-ligand interactions and use this for 
the design of novel, receptor subtype selective, potent and metabolically 
suitable drugs.  
 
The general aim of the current thesis was development and validation of 
novel assay systems for studies of the binding properties of novel melanocortin 
ligands and for characterisation of receptor-ligand interaction mechanisms that 
would enhance our general understanding of the melanocortin system.  
To address this general aim, several particular tasks were proposed (with 
special attention paid to the MC4 subtype): 
 Comparison of ligand binding and secondary messenger activation 
properties of new melanocortin receptor active compounds 
 Implication of novel radioligand for characterisation of the MC4 receptor 
ligand binding mechanism 
 Implication of a fluorescence anisotropy-based assay for characterisation of 
the MC4 receptor ligand binding properties 
 Implication of budded baculoviruses as a receptor source for characterisation 
of the MC4 receptor ligand binding properties in a fluorescence anisotropy-
based assay 
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4. MATERIALS AND METHODS 
4.1. Cell cultures 
 B16-F1 murine melanoma cells were cultured as a monolayer culture in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with a 10% 
heat-inactivated foetal calf serum (FBS) at 37 C in a humidified 5% CO2 
cell incubator. Cells from frozen stocks were used in MC1 receptor 
radioligand binding assays (Paper I), whereas freshly cultured cells were 
used for assessment of ligand functional effects on MC1 receptor in cAMP 
assay (Paper I).  
 COS-1 cells were grown as monolayer culture in DMEM supplemented with 
10% heat-inactivated FBS at 37 C in humidified 5% CO2 cell incubator. 
50 confluent COS-1 cells were transiently expressed with either one of the 
recombinant human MC3, MC4 and MC5 receptor DNA (described earlier 
(Schiöth et al., 1997)) by using Lipofectine reagent (Gibco-BRL) according 
to the manufacturer’s instructions. After 48 h transfected COS-1 cells were 
used for determination of ligands’ functional effects in a cAMP assay 
(Paper I) or used for membrane preparation (Paper II). 
 Sf9 cells were grown: 
‒ in 50–100 ml Sf-900 II medium at 27 C in small spinner bottles (250 ml) 
as described earlier (O’Reilly et al., 1992). Recombinant human MC3, 
MC4 and MC5 baculoviruses (prepared as described in (Kopanchuk et al., 
2005)) were added to the cell culture (2–3  106 cells/ml) and the 
incubation continued for additional 72 h before harvest, centrifugation 
and membrane preparation or freezing of concentrated cell suspension. 
Cells from frozen stocks were used for assessment of tertiary amides’ 
binding properties in radioligand binding assays (Paper I). Sf9 cell 
membrane preparations were used in MC4 receptor kinetic radioligand 
binding experiments (Paper II). 
‒ in serum-free insect cell medium (BD BaculoGold Max-XP) with supple-
mentation of 25 U/ml penicillin and 25 g/ml streptomycin. For 
production of cells expressing MC4 receptors, 150 ml of Sf9 cell 
suspension in a 500-ml Erlenmeyer flask at a density 2  106 cells/ml was 
infected with a high-titre supernatant of baculovirus encoding the human 
MC4 receptor and grown for 4 to 5 days with shaking at 120 rpm on an 
orbital shaker at 27 C in a humidified atmosphere. Then cells were 
harvested, centrifuged and cell membrane preparation prepared for usage 
in FA-based ligand binding assays (Paper III). 
‒ in serum-free insect cell growth medium EX-CELL 420 in Celstir spinner 
flasks (stirring rate 115 rpm) at 27 °C in a nonhumidified environment. 
For the production of budded baculoviruses that display MC4 receptors 
on cell membrane envelope, 500 ml of Sf9 cell suspension at a density of 
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2 × 106 cells/ml was infected with a high-titre supernatant of recombinant 
baculovirus encoding the human MC4 receptor at a multiplicity of 
infection MOI = 3 and was grown for ≈ 96 h. Then supernatant fraction 
of cell suspension was used for preparation of the MC4 receptor budded 
baculoviruses for FA-based ligand binding assays (Paper IV).  
 
 
4.2. Receptor preparations 
4.2.1. Cell membrane preparations 
Membrane preparations of the MC4 receptors from Sf9 and COS-1 cells for 
kinetic radioligand binding experiments were prepared as following (Paper II): 
COS-1 cells (48 h post transfection) and Sf9 cells (72 h after infection with 
recombinant MC4 receptor baculovirus) were collected by centrifugation at 
800  g for 5 min and homogenised with a glass–Teflon Dounce homogeniser 
(five times by 10 strokes with 30 s intervals) in an ice-cold buffer solution (B1) 
containing 20 mM Na-HEPES, 1 mM CaCl2, 0.1 mM phenylmethylsulfonyl 
fluoride, 0.25 mM benzamidine, 1 g/ml leupeptin, 1 g/ml aprotinin, 1 g/ml 
soybean trypsin inhibitor, pH 7.4. The homogenate was centrifuged at 700  g 
for 5 min at 4 C, the pellet was then homogenised once more in B1 solution 
and centrifuged. The supernatants were combined; membranes were collected 
by centrifugation at 70,000  g for 60 min at 4 C, washed once with a B1 
buffer, resuspended in new B1 and recentrifuged. The final pellet was 
resuspended in a B1 buffer at a concentration of 1–3 mg of protein/ml and 
aliquots were stored at 80 C. Protein was determined using the Bradford 
method (Bradford, 1976) using bovine serum albumin (BSA) as the standard. 
MC4 receptor Sf9 cell membrane preparations for FA-based ligand binding 
assays were prepared as following (Paper III): 
4 to 5 days after infection of cells with a high-titre recombinant baculovirus 
encoding the MC4 receptor, Sf9 cells were collected by centrifugation at 
1000  g for 10 min and homogenised using a Bandelin Sonopuls sonicator 
(70 W, 70%, three passes by 10 s each) in ice-cold buffer (B2), which contained 
20 mM Na–Hepes, 1 mM CaCl2, and a Complete EDTA-Free Protease Inhibitor 
Cocktail (Roche Applied Science) according to the manufacturer’s description, 
pH 7.4. The homogenate was centrifuged at 30,000  g for 40 min at 4 C, and 
the pellet was homogenised and centrifuged once more as described above. The 
final pellet containing Sf9 cell membranes was resuspended in a B2 solution in 
a ratio of 1:15 in regard to the initial cell suspension volume, corresponding to a 
concentration of approximately 1 mg of protein/ml, and aliquots were stored at 
80 C until used. Protein content was determined using the Bradford method 
with BSA as the standard. 
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4.2.2. Budded baculovirus preparation 
For the production of budded baculoviruses (BBV) that display MC4 receptors 
on their membrane envelope (Paper IV), 500 ml of Sf9 cell suspension at a 
density of 2  106 cells/ml was infected with a high-titre supernatant of 
corresponding baculovirus at a multiplicity of infection MOI = 3 and was grown 
in a spinner flask for ≈ 96 h with an agitation of 115 rpm at 27 °C in a 
nonhumidified environment. The supernatant fraction that contained BBVs was 
then collected after the centrifugation of cell suspension at 1000  g for 10 min. 
Following centrifugation of the collected supernatant at 48,000  g for 40 min 
revealed pellet that contained BBVs. This was carefully washed with sterile 
incubation buffer (IB), which contained 20 mM Na-HEPES, 1 mM CaCl2, 
Complete EDTA-Free Protease Inhibitor Cocktail (Roche Applied Science) 
according to the manufacturer’s description, and 0.1% Pluronic F-127, pH 7.4. 
Then, the obtained pellet was resuspended in sterile IB in a ratio of 1:20 in 
regard to the initial cell suspension volume. The obtained baculovirus 
preparations were aliquoted and aliquots stored at 90 °C until used for 
analysis.  
The same scheme was used for production of BBVs displaying human NPY1 
receptor (neuropeptide Y receptor Y1)) on their membrane envelope with the 
exception that the supernatant fraction was collected 48 h post infection. 
 
 
4.3. Recombinant baculovirus construction 
Cloning of baculoviruses containing human MC3 (Gantz et al., 1993a), MC4 
(Gantz et al., 1993b) and MC5 (Chhajlani et al., 1993) receptor genes was 
performed as described in (Kopanchuk et al., 2005). Obtained baculovirus 
vectors were used for expression of these receptors into Sf9 cells, which were 
further used in radioligand binding experiments (as whole cells (Paper I) or 
membrane preparation (Paper II)). Shortly, cDNA (in pcDNA3.1) of three 
human MC receptors were subcloned into the HinDIII–XbaI site of the 
pFdHPhMC2R vector and transformed into DH10Bac-competent cells for 
transposition into baculovirus DNA. All vector inserts were sequenced. 
Recombinant baculovirus DNAs was transfected into Sf9 cells using cellfectin. 
Viruses were amplified about 2−3 times and stocks were prepared. Then 
baculovirus single clone purification procedures were performed and the clonal 
baculoviruses (encoding Flag-MC receptors) yielding the highest receptor 
expressions were selected and used further.  
To obtain recombinant MC4 receptor baculoviruses further used in FA-based 
ligand binding assays (Paper III, IV), human MC4 receptor cDNA in 
pcDNA3.1 was subcloned into the EcoRI–XhoI site of the pFastBac1 vector 
and transformed into DH10Bac-competent cells. All plasmid constructs were 
sequenced. Recombinant baculovirus was generated by homologous recombi-
nation via transfection of 7  105 insect cells with 5 g of purified recombinant 
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bacmid DNA in the presence of 16 l of ExGen500 in 35-mm tissue culture 
plates. Viruses were harvested after 72 h of incubation at 27 C and amplified at 
a multiplicity of infection of 0.1 in suspension culture until high-titre virus 
supernatants reached. Large-scale virus stocks were harvested 96 h post 
infection by centrifugation at 1000  g for 10 min, and supernatants were stored 
at 4 C. Virus titres were estimated by standard plaque assay or by titration 
assay based on viable and infected cell size differences (Janakiraman et al., 
2006); for more details see (Reinart-Okugbeni, 2012).  
The same scheme was utilised for generation of NPY1 receptor recombinant 
baculovirus constructs, with the exception that cDNA (in pcDNA3.1, obtained 
from the University of Missouri-Rolla cDNA Resource Center) was subcloned 
into the BamHI-XbaI site of the pFastBac1 vector. 
 
 
4.4. Radioligand binding assays 
Screening of binding of tertiary amides to human MC receptors (Paper I) were 
performed using [
125
I]-NDP-α-MSH radioligand binding as described earlier 
(Schiöth et al., 1995). Briefly, each of the radioligand binding assays comprised 
a dilution series of 12 concentrations in duplicates, and each compound was 
analysed with at least two repeats. B16-F1 murine melanoma cells (naturally 
expressing MC1 receptors) or Sf9 cells expressing either one of the recombinant 
human MC3, MC4 or MC5 receptors were taken from frozen stocks and washed 
with binding buffer B3 (minimum essential medium with Earle’s salts, pH 7.0, 
0.2% BSA, 1 mM 1,10- phenanthroline, 0.5 mg/l leupeptin and 200 mg/l 
bacitracin). The assays were performed in 96-well binding plates. To each well 
approximately 50,000 cells, 0.5 nM [
125
I]-NDP-α-MSH (giving about 50,000 
cpm) and appropriate concentrations of tertiary amide in binding buffer were 
dispensed. The plates were then incubated for 1 h at 37 C, centrifuged 
(3500  rpm for 5 min at 5 C) and supernatant aspirated in order to separate the 
free radioligand from the cell bound radioligand. The cells were washed then 
with an ice-cold B3 buffer, detached from the plates with 0.1 N NaOH and the 
radioactivity was counted in a Wallac, Wizard automatic gamma counter.  
Radioligand binding assays on Sf9 cell membranes or COS-1 cell 
membranes expressing MC4 receptors (Paper II) were performed by incubation 
of membranes (5 g protein/100 l in equilibrium binding or 40 g protein/ 
700 l in kinetic experiments) in the incubation buffer containing 20 mM  
K-HEPES, 5 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 1 mg/ml BSA and 
0.5 mM Na-acetate (pH 7.4). Binding of [
125
I]-NDP-α-MSH or [125I]THIQ was 
determined after incubation of membranes with different concentrations of 
radioligand (1 pM–6 nM), or in the case of displacements with a fixed 
concentration of radioligand (0.6 nM) and different concentrations of competing 
ligands. Incubations with [
125
I]-NDP-α-MSH were carried out for 3 h at 25 C 
and terminated by rapid filtration through 0.3% polyethyleneimine and 1 mg/ml 
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BSA pretreated GF/B glass–fibre filters using a Brandel cell harvester, followed 
by three washings with 5 ml of ice-cold 50 mM Tris–HCl buffer (pH 7.4). 
Incubations with [
125
I]THIQ were carried out for 1 h at 25 C and terminated by 
filtration through non-pretreated filters. Ice-cold 10 mM Na-acetate buffer 
(pH 4.5) used for the washing of filters was found to be optimal to minimise the 
amount of non-specifically bound [
125
I]THIQ. Non-specific binding was 
determined in the presence of 3 M I-NDP-α-MSH or I-THIQ. 
Radioligand association kinetics was determined after addition of the 
radioligand to the membrane suspension in the incubation buffer. At timed 
intervals aliquots (200 or 500 l) were filtered on GF/B filters and washed with 
the corresponding buffer. Non-specific binding was determined by incubation of 
the membranes with the radioligand and 1000-fold excess of non-labelled ligand. 
Dissociation experiments were performed after preincubating the membrane 
suspension with [
125
I]-NDP-α-MSH (0.6 nM) or [125I]THIQ (0.2 and 0.6 nM) for 
appropriate times at 25 C. Dissociation was then initiated by adding non-
labelled NDP-α-MSH (final concentration 3 or 100 M) or I-THIQ (final 
concentration 3 M), or hAGRP(83-132) (final concentration 0.8 or 10 M), or 
by 100-fold dilution of the reaction’s medium. At timed intervals aliquots were 
filtered on GF/B filters and washed with the corresponding buffer. 
 
 
4.5. cAMP assay 
The ability of compounds of interest to influence the levels of cAMP (Paper I) 
was, for the MC1 receptor, assessed in B16-F1 murine melanoma cells that 
express the MC1 receptor naturally, or in transiently transfected COS-1 cells 
with MC3, MC4 and MC5 receptors. In brief, cells were harvested and incubated 
for 20 min at 37 C in 50 l FBS-free DMEM containing 0.5 mM 3-isobutyl-1-
methylxanthine and appropriate concentrations of substances of interest. cAMP 
was then extracted from cells by adding 4.4 M perchloric acid to achieve a final 
concentration of 1.25 M. After 5 min the samples were neutralised with 5 M 
KOH/1 M Tris and centrifuged at 3000  rpm for 5 min at 20 C. After 
centrifugation 50 l of supernatants or cAMP standards ranging from 0.2 to 
250 nM were added to 96-well microtitre plates. The cAMP concentration was 
measured by a bovine adrenal cAMP binding protein competitive binding assay 
using [
3
H]-cAMP (specific activity 24 Ci/mmol) as labelled ligand (Nordstedt 
and Fredholm, 1990). In brief, [
3
H]-cAMP (0.14 pmol, giving approximately 
11,000 cpm), the sample or cAMP standard and the binding protein were 
incubated at 4 C for 150 min after which the incubates were harvested by 
filtration on Whatman GF/B filters using a semiautomatic Brandel cell 
harvester. Each filter was rinsed with 10 ml ice-cold 50 mM Tris∙HCl (pH 7.4), 
punched out and placed into scintillation vials with scintillation fluid, and the 
radioactivity of bound [
3
H]-cAMP was counted and the concentration of cAMP 
in samples was calculated. 
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4.6. FA-based ligand binding assays 
FA measurements with Cy3B-NDP-α-MSH (Paper III, IV) (GE Healthcare 
Life Sciences, Sweden) were performed in the simplest buffer solution required 
for ligand binding to MC4 receptor (20 mM Na-HEPES, 1 mM CaCl2, Complete 
EDTA-Free Protease Inhibitor Cocktail (according to the manufacturer’s 
description, Roche Applied Science) and 0.1% Pluronic F-127 (Invitrogen), pH 
7.4). The detergent has been found to be essential for stabilising the signal 
during anisotropy measurements and has no significant influence on the 
properties of NDP-α-MSH binding to the MC4 receptor (Do et al., 2006). 
Whereas lower fluorescence intensity and anisotropy signal stability were found 
for TAMRA-NDP--MSH (AnaSpec, USA) in this buffer solution (Paper III). 
Increasing the ionic strength of the buffer (addition of NaCl and/or KCl) 
significantly improved fluorescence signal characteristics of TAMRA-NDP--
MSH, and modified Krebs–Ringer buffer (135 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 0.1 mg/ml.BSA, and 11 mM Na-Hepes, pH 7.4) 
supplemented with Complete EDTA-Free Protease Inhibitor Cocktail and 0.1% 
Pluronic F-127 was found to be optimal for assays with this ligand. 
Stocks of the fluorescent ligands in dimethyl sulphoxide (DMSO) were 
stored at −20 C and diluted with appropriate assay buffers on the day of the 
experiment. The concentration of fluorescent ligands was confirmed by 
absorbance readings of Cy3B (ε558 = 130,000 M
−1 
cm
−1
) and TAMRA 
(ε547 = 80,000 M
−1 
cm
−1
). Black 96-well half area, black flat bottom polystyrene 
NBS microplates (Corning, Product No. 3993) were found to give optimal 
results for our assays (low background fluorescence and low adsorption of 
ligands onto the plastic surface) and were used in all experiments. 
Assays were performed in a total volume of 100 μl at 27 °C (optimal 
temperature for growing of Sf9 cells) on a PHERAstar (BMG Labtech, 
Germany) microplate reader using an optical module with excitation and 
emission filters of 540 nm (slit 20 nm) and 590 nm (slit 20 nm), respectively. 
The dual emission detection mode allows the simultaneous recording of 
intensities that are parallel (I||) and perpendicular (I) to the plane of excitation 
light. Sensitivities of channels (G factor) were corrected with a gain adjustment 
of the photomultiplier tubes (PMTs) using erythrosine B as a standard 
(Thompson et al., 2002). 
All experiments were carried out in the kinetic mode and reactions were 
started by the addition of receptor preparation (Sf9 cell membranes or BBVs) to 
the microplate wells that contained the fluorescent ligand with or without 
competing ligands, and fluorescence intensities were registered at the 
appropriate time points. Unless otherwise stated, approximate MC4 receptor 
concentration used per well was 1.5 nM in case of membrane preparation used 
and 0.5 nM when BBVs were used as a receptor source. 
The ligand-specific effects were measured in the presence (nonspecific 
binding) or absence (total binding) of an excess of NDP-α-MSH (3 μM), and 
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specific binding was defined as the difference between these values. In addition, 
the background fluorescence of the assay, which was caused by membranes, 
buffers, competing ligands etc., was measured in the absence of the fluorescent 
ligand and was subsequently subtracted separately from all channels of all the 
total and nonspecific binding data, resulting in background-corrected values. 
Steady-state FA signals at time   after the initiation of the binding reaction was 
calculated as parameter      from the Eq. 1. 
Concentration dependent binding of both, Cy3B-NDP-α-MSH and TAMRA-
NDP--MSH, to MC4 receptors was determined by varying the concentration of 
receptor and keeping the ligands’ concentration constant (Paper III) or, in case 
of Cy3B-NDP-α-MSH used in tandem with BBVs (Paper IV), also by varying 
the concentration of Cy3B-NDP-α-MSH and keeping the receptor’s 
concentration constant. 
In the case of competitive binding experiments, fixed concentrations of 
fluorescent ligands (1 nM) and receptor preparations were incubated with 
increasing concentrations of the MC4 receptor agonists (NDP-α-MSH and  
β-MSH (AnaSpec, USA), α-MSH, Ro27-3225, MT II, HP-228 and H-6268 
(Bachem AG, Switzerland), and I-THIQ (kindly provided by Dr. Felikss 
Mutulis (Mutulis et al., 2003))) and antagonists (HS-024 (Tocris Bioscience, 
UK), SHU9119, JKC-363 and H-2716 (BachemAG, Switzerland)), and 
reactions were followed in the kinetic mode as described above. The 
experiments for all studied MC4 receptor ligands were performed in duplicates 
using a 10-point dilution series. 
The dissociation kinetics were measured after the preincubation of the 
receptor preparation with 1 nM Cy3B-NDP-α-MSH or TAMRA-NDP--MSH 
for certain time period. Subsequently, the dissociation was initiated by the 
addition of 3 μM NDP-α-MSH, 3 μM SHU9119, 3 μM I-THIQ or 10 mM 
EDTA (final concentrations), and the reactions were followed in the kinetic 
mode as described above. 
 
 
4.7. Data analysis 
For the analysis of experimental data the BindAid software (Paper I) (Wan 
System AB, Umeå, Sweden), GraphPad Prism 4.03 (Paper II) or 5.00 (Paper 
III, IV) (GraphPad Software Inc., San Diego, CA, USA) or MATLAB 7.1 
programme (Paper IV) (MathWorks, Inc., Natick, MA, USA) was used (see 
original publications for more details).  
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5. RESULTS AND DISCUSSION 
As MC receptors participate in the regulation of a wide variety of different 
physiological functions, selective and high-affinity MC receptor ligands would 
be perspective drug candidates for the treatment of diseases regulated by these 
receptors. In order to obtain non-peptide, MC receptor active compounds 
suitable for medical use, the library of 210 tertiary amides (compounds that 
have centrally located amide moiety with three different substituents) was 
designed and synthesised in Uppsala University in the laboratory of Prof. Jarl 
Wikberg (Paper I). We tested these compounds on their ability to bind to the 
four melanocortin receptor subtypes MC1, MC3, MC4 and MC5. Almost all 
synthesised compounds inhibited [
125
I]-NDP-α-MSH binding on recombinant 
human MC receptors with affinities in the micromolar range. Despite 
considerable structural differences, most of the studied tertiary amides showed 
quite similar binding affinities for all the MC receptors tested. Only few of them 
were selective for one of the receptor subtypes having selectivity pattern 
MC1  MC4 and MC5  MC3. In order to determine whether synthesised tertiary 
amides are MC receptor activators or inhibitors, some of the title compounds 
were tested for their ability to promote or block the accumulation of cAMP in 
cells expressing different MC receptor subtypes. In these functional assays all 
the studied compounds demonstrated the ability to inhibit the increase of cAMP 
accumulation caused by full agonist α-MSH. In some cases the inhibition was 
incomplete as the remained level of cAMP was higher than the control level of 
cAMP. These observations led to the notion that tested compounds act as MC 
receptor antagonists and/or partial agonists, but the data available did not allow 
for clearly distinguishing these two options.  
In the course of our studies aiming at the development of MC receptor 
subtype selective organic agonists and antagonists (Mutulis et al., 2002a, 2002b, 
2005), radioligand binding assays have had an essential role. Historically, MC 
receptor radioligand binding assays have been developed for intact cells, which 
have relatively high nonspecific binding and require substantial amounts of 
living cells. As we were interested in improving the accuracy and sensitivity of 
our radioligand binding assays, we proposed that using a simpler system, where 
the receptors are confined in a membrane fraction rather than in whole cells, 
would be beneficial as less confounding effects should become introduced by 
ligand diffusion into the cells, cell metabolism, etc. We introduced membrane 
preparations from recombinantly transfected Sf9 cells as a suitable, adequate 
and simpler model system for studies of the MC receptor ligand binding in 
radioligand binding assays (Kopanchuk et al., 2005, Mutulis et al., 2005). 
During the characterisation and evaluation of these membrane preparations we 
found that the presence of Ca
2+
 ions is mandatory for achieving specific [
125
I]-
NDP-α-MSH binding to the melanocortin receptors (Kopanchuk et al., 2005). 
Moreover, [
125
I]-NDP-α-MSH demonstrated heterogeneous and incomplete 
dissociation kinetics from the binding with MC receptor complexes (in different 
13
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extent for different receptor subtypes). Besides that, [
125
I]-NDP-α-MSH in 
competition with 11 MC receptor peptides gave grossly different shapes of 
competition curves ranging from shallow to super-steep. As the “extent” of 
heterogeneity varied for different peptides and receptor subtypes, we proposed 
that ligand binding to the MC receptors is governed by a complex dynamic 
homotropic cooperative regulation. These findings indicated that more attention 
has to be paid to the kinetic characteristics of ligand binding to the MC 
receptors as well. Despite the fact that [
125
I]-NDP-α-MSH has been widely used 
for studies of the MC receptors and their active compounds, we realised that 
very little was known however about its own kinetic properties. Our recently 
synthesised radioiodinated low molecular weight high-affinity MC4 receptor 
selective ligand [
125
I]THIQ (Mutulis et al., 2003) gave us the chance to compare 
the properties of two radioligands in MC4 receptor-directed studies. We used 
these two radioligands, [
125
I]-NDP-α-MSH and [125I]THIQ, together in one 
study to characterise ligand binding mechanism to MC4 receptor (Paper II). 
Whereas the kinetic characteristics of used ligands were different, they both 
demonstrated heterogeneity in their binding patterns to MC4 receptors. The 
association kinetics of [
125
I]-NDP-α-MSH was slow and heterogeneous, where 
the rate constant for slower component did not depend on the radioligand 
concentration, whereas the rate constant for the faster component depended 
linearly on the [
125
I]-NDP-α-MSH concentration. Dissociation of [125I]-NDP-α-
MSH from the complex with the MC4 receptor was biphasic and incomplete as 
it reached the plateau – the apparent irreversibility of bound ligand can be 
considered as a practically non-dissociable fraction; whereas the rate of 
dissociable fraction was independent from the preincubation time (an 
average                    
  ). On the contrary, [
125
I]THIQ demon-
strated considerably faster association kinetics, which proportionally accel-
erated within the increase of [
125
I]THIQ concentration. Due to the practical 
limitations of the radioligand binding method for the determination of very fast 
kinetics, no heterogeneity in [
125
I]THIQ association kinetics was observed in the 
concentration range used. However, dissociation of this ligand from the 
complex with the MC4 receptor was complete, fast and biphasic when initiated 
by non-radioactive I-THIQ. The analysis revealed that part of the [
125
I]THIQ 
dissociates very fast with          , while another part released with a 
          . But more intriguingly, when dissociation of [
125
I]THIQ was 
initiated by an excess of non-labelled peptide ligand I-NDP-α-MSH, a hetero-
geneous dissociation pattern was also observed, but the dissociation rate of the 
second phase became considerably slower, having a            . When 
human AGRP(83-132) was used as a displacer, the dissociation rate of the 
second phase became even slower with the half-life being more than 5 h. 
Moreover, when displacement of [
125
I]-NDP-α-MSH and [125I]THIQ was 
studied, the peptide and low molecular weight non-peptide ligands 
demonstrated different abilities to compete with either [
125
I]-NDP-α-MSH or 
[
125
I]THIQ for binding to MC4 receptors (Fig. 5).  
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Figure 5. Differences in the apparent affinities of peptide ligands (I-NDP-α-MSH, HS131, 
HL-peptide) and low molecular weight non-peptide ligands (I-THIQ, THIQ, MSY-3, 
MSY-6) for the MC4 receptor measured in competition with [
125
I]-NDP-α-MSH and 
[
125
I]THIQ. Data are presented as differences of negative logarithms of means of apparent 
ligand binding constants to MC4 receptors measured in competition with [
125
I]-NDP-α-
MSH (pKi[
125
I]-NDP-α-MSH) and [125I]THIQ (pKi[
125
I]THIQ), respectively. 
 
 
In competition with [
125
I]-NDP-α-MSH the peptide ligands had up to 20,000-
fold higher apparent affinities than in competition with [
125
I]THIQ. However, 
the low molecular weight ligands demonstrated almost similar abilities to 
compete with both radioligands, only with a slight, 1.5–12-fold preference for 
inhibiting the binding of [
125
I]THIQ (Fig. 5). 
The nature of the obtained results indicated that MC4 receptor-ligand 
interactions are complex and that at least two ligand-binding sites are inter-
connecting. Our attempts to explain the obtained results directed us to the 
development of a minimal model of the MC4 receptor-ligand interactions that 
can account for all experimental data. It was proposed that interconnecting 
ligand binding sites are located on individual/separate receptor subunits within 
the dimeric/oligomeric complex of the MC4 receptor. According to this model 
(Fig. 6), MC4 receptors exist as preformed dimers RR and the binding of a 
ligand may occur only on one of the receptor subunits at a time. After 
conformational changes caused by the ligand binding to either one of the 
receptor units, the ligand molecule becomes “locked” into the complex and 
herewith it opens the possibility for the second ligand molecule to bind to the 
other receptor subunit. When both receptor units have bound [
125
I]-NDP-α-
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MSH, the radioligand can be released only from the non-isomerised unit, while 
it remains practically irreversibly bound to the other, isomerised unit due to the 
very slow de-isomerisation rate of the complex R
*LR → LRR. This was also 
supported by results from the experiment where dissociation of [
125
I]-NDP-α-
MSH from the complex with the MC4 receptor was initiated by dilution – 
similar, biphasic and incomplete, dissociation patterns were observed and the 
off rate of the dissociable fraction was 0.005 ± 0.001 min–1. Whereas, 
[
125
I]THIQ dissociation studies revealed that the release of the slower 
component of [
125
I]THIQ was remarkably retarded when dissociation was 
initiated by I-NDP-α-MSH or hAGRP(83-132) – in these cases the rate limiting 
step of [
125
I]THIQ dissociation is reaction R
*LRL → R*LR (i.e. release of  
I-NDP-α-MSH from the non-isomerised site). This was supported by the fact 
that the rate constant of the slower component for the [
125
I]THIQ dissociation in 
the presence of I-NDP-α-MSH (                   
  ) coincided with 
the faster component’s rate constant of [125I]-NDP-α-MSH dissociation. 
 
 
 
Figure 6. Schematic illustration of the model of ligand binding to tandemly arranged 
ligand binding sites on the MC4 receptor dimer and the conformational transformations 
associated therewith. 
 
Thus, the slow binding kinetics of [
125
I]-NDP--MSH and the presence of 
interconnecting MC4 receptor binding sites becomes critical when [
125
I]-NDP-
-MSH is used for the determination of binding potencies of new MC4 receptor 
active ligands. Gross differences in the apparent potencies of the same ligand 
were observed depending on the radioligand used in competition assays (Fig. 5). 
This probably would lead to the situation that some of the potentially 
perspective compounds are “lost” in radioligand HTS assays. That is why the 
kinetic properties of the competitor should also be taken into account in the 
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interpretation of data from competition binding experiments, but the filtration 
step-implicating radioligand binding assays are limited for the possibility of 
measuring the kinetics of the competing ligand. Developments in fluorescence-
based ligand binding methods allow for achievement of even higher sensitivity, 
throughput, experimental “flexibility”, etc., in comparison with radioactive 
methods. We implicated the FA-based assay system for studies of the MC 
receptors (Paper III, IV). This method allowed us online monitoring of ligand 
binding reactions to the MC4 receptor and characterisation of binding dynamics 
to the receptor of both labelled and non-labelled ligands. Obtained kinetic 
information allows for estimation of more correct binding parameters essential 
for understanding ligand binding and its regulation mechanisms and design of 
new drugs with desirable properties. The binding properties of two different 
red-shifted fluorophore-labelled peptide ligands, Cy3B-NDP--MSH and 
TAMRA-NDP--MSH, to MC4 receptors in membranes of Sf9 insect cells were 
compared and characterised (Paper III). The Cy3B-NDP--MSH demonstrated 
improved assay performance in comparison with TAMRA-labelled NDP--
MSH having higher photostability, insensitivity to buffer properties, and better 
signal-to-noise ratio. Even though the FA signal of TAMRA-NDP--MSH was 
not stable, the binding of both ligands to MC4 receptors in Sf9 cell membranes 
was saturable and had high affinity. In competition binding assays all studied 
MC4 receptor-specific non-labelled ligands displaced fluoroligands’ binding in a 
concentration-dependent manner with potencies in agreement with the order of 
their pharmacological activities. However, due to the slow kinetic characte-
ristics of labelled NDP--MSH (fluorescent as well as radioactive) it is practi-
cally impossible to reveal equilibrium binding constants from competition 
binding experiments. Nevertheless, the FA assay system allows for monitoring 
of the receptor-ligand interaction process in real time thus giving the possibility 
to obtain at least rough estimates concerning the competitive ligand’s affinity, 
but also binding kinetics. For example, on-line monitoring of Cy3B-NDP-- 
MSH competition binding dynamics revealed that even 3 h of incubation for 
some of the ligands is not enough to reach the reaction’s/interaction’s 
equilibrium as apparent affinities (expressed as pIC50 values in Fig. 7) were still 
changing in time. Ignoring this kinetic factor may lead to over- or underesti-
mation of the compound’s apparent affinities. 
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Figure 7. Dynamics of competition binding of Cy3B-NDP--MSH with NDP--MSH 
(A) and -MSH (B) to the MC4 receptor in Sf9 cell membranes. Presented data 
correspond to FA values determined 26 min (), 56 min (), 76 min (), 116 min 
(), 146 min (), 176 min (), 226 min () and 276 min () after the initiation of 
competition reaction. Calculated pIC50 values (negative logarithm of the competitive 
ligand concentration causing 50% inhibition of anisotropy change caused by Cy3B-
NDP--MSH binding to the receptor) are indicated in insets. 
 
Although different GPCR preparations have been employed for FA assays, 
including whole cells (Wilkinson et al., 2001), membranes from overexpressed 
cells (Huwiler et al., 2010; Harris et al., 2003; Cornelius et al., 2009; Do et al., 
2006), solubilised receptors (Rossi and Taylor, 2011) and GPCRs inserted into 
VLPs (Jones et al., 2008), implementation of Sf9 cell membranes with MC4 
receptors allowed us to achieve high levels of receptor protein expression 
(33 ± 3 pmol/mg protein). Thus, we were able to overcome one of the main 
55 
obstacles hindering the wider use of FA method for general studies of GPCRs 
as well as for ligand screening purposes, namely low receptor concentration in 
receptor preparations. Such a high receptor expression level provided a good 
assay window and led the influence of light scattering and autofluorescence 
from cellular components to be minimal because small amounts of membranes 
were used in assays. However, although good experimental conditions can be 
achieved in FA-based assays with Sf9 cell membrane preparations, homo-
genised membranes cannot be considered a homogeneous assay system – rather 
a mixture of lipoparticles of different shapes and sizes that range from a few 
tens of nanometres to more than a micrometre in diameter (Bailey et al., 2009). 
Additionally, the orientation of receptor proteins within such a lipoparticles is a 
controversial issue with limited control as well. In contrast to soluble 
receptor/protein studies, the generation of isotropic assay systems, where all 
receptor spatial orientations are evenly distributed and present in reaction’s 
mediums, is more challenging when membrane receptors are studied. However, 
in the case of BBVs that we introduced as MC4 receptor carriers in FA-based 
ligand binding assays (Paper IV), the initial isotropic conditions are primarily 
fulfilled (see Box 1). Cy3B-NDP--MSH on obtained BBV preparation 
demonstrated MC4 receptor specific binding with improved FA assay 
performance and stability – the autofluorescence and light-scattering from the 
BBV preparation was more than five times lower than that observed from 
homogenised Sf9 cell membrane preparation with MC4 receptors. Moreover, 
BBV preparation was highly stable in solutions and demonstrated long-lasting 
FA signal stability – the signal remained stable for at least 12 h after the 
initiation of the binding reaction, which is advantageous for assays where 
kinetically slow ligands are studied or when large numbers of samples are being 
screened at the same time. For the comparison, when membrane preparations 
from the same Sf9 cell system were used as receptor sources, the FA signal 
started to decrease after only 3 h of incubation (Paper III).  
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Box 1| Budded baculoviruses as a tool for homogeneous FA-based ligand binding 
assays 
 
 
Baculovirus Surface Display (BVSD) technology is based on the ability of 
baculoviruses to express foreign proteins on both the surface of insect cells and their 
envelope. Budded baculoviruses (BBV) are produced during the insect cell infection 
cycle as nucleocapsids that bud from the insect cell surface. Baculoviruses are rod-
shaped viruses (approximately 40–50 nm in diameter and 200–400 nm in length) that 
are surrounded by a double lipid bilayer envelope, which is derived directly from the 
host cell surface and carries membrane proteins from the host cell surface. Thus, 
BBVs can be considered as an essentially soluble cell-free system in which 
membrane proteins, including G protein-coupled receptors, are displayed on the 
surface of BBVs in their native conformation and environment. Moreover, BVSD 
represents more or less a “one size fits all” solution – viruses that are used for the 
delivery of genetic information into the cells and for the expression of receptors are 
also used for the exposure of those receptors on their own surfaces. Furthermore, 
manipulations with baculoviruses could be conducted in Biosafety Level 1 conditions 
(they are neither hazardous for the environment nor dangerous for humans), which 
considerably simplifies the handling and maintenance of baculovirus/insect cell 
system. Cost-effective, high expression level, large scale production possibilities 
make this system a highly attractive tool for the assessment of receptor-ligand 
binding interactions in fluorescence-based assays. We have shown that BBV fraction 
from Sf9 cells can be successfully used as a source of GPCRs in steady state FA-
based assays and that this preparation has several advantages over other conventional 
receptor preparations (Paper IV). 
 
 
To achieve sufficient changes of signal, FA assay demands that reactions are 
performed under second-order conditions where ligand and receptor con-
centrations are comparable ([L] ≈ [R]). This causes the excessive fluorescent 
ligand depletion during the course of the reaction which has to be taken into the 
account in the mathematical description of the interaction’s processes. Here 
usual approximations like application of pseudo-first order reaction conditions, 
often used in radioligand binding assays, cannot be used anymore and this 
considerably complicates the data analysis. Besides specific binding, non-
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specific binding sites may also contribute to the depletion of fluorescent ligand 
thus producing significant biases in results, if not taken into account. We 
proposed sets of equations for global analysis of direct and competitive 
equilibrium binding experiments as well as for binding kinetics (Paper IV). For 
analysis of binding kinetics we adopted analytically solved closed form 
equations for the simplest case of second-order reversible reactions (Malatesta, 
2005). 
The global data analysis from multiple variable experiments (Fig. 8) can 
significantly increase the content of accessible information if comparing with 
that from single variable experiments. However, the global data analysis 
approach also demands very good assay quality with initial isotropy conditions. 
Implementation of BBVs largely fulfilled these requirements. In the current 
study we performed multivariable global data analysis based on the simple 
second-order kinetic mechanistic model that assumes maximally three 
fluorescent ligand states (n = 3): free ligand, receptor-bound ligand and non-
specifically bound ligand. The FA signal can be defined as the weighted sum of 
the anisotropy values    for these different fluorescent ligand states  : 
  
      ∑      
 
       (2)  
 
The sum of fractions is 1 and the weighting parameter       describes the 
fractional proportion of the each fluorescent ligand’s state in the corresponding 
time point. Mathematical description of each particular fraction’s behaviour in 
the course of reaction could be found in the Supplementary materials of Paper 
IV. The applied mathematical approach (simultaneous fitting of two data 
surfaces (overall/total and nonspecific binding signals) as a function of both, 
time and receptor concentration; Fig. 8) allowed for determination of the 
receptor concentration, affinity and kinetic parameters of fluorescent ligand 
binding and state anisotropy values for different fluorescent ligand populations. 
We have performed two types of receptor-ligand titration experiments: by 
keeping fluorescent ligand concentration constant (1 or 0.5 nM) and varying the 
concentration of receptor, or by keeping the amount of receptors constant and 
varying the concentration of Cy3B-NDP-α-MSH. It was revealed that at low 
Cy3B-NDP-α-MSH concentrations the interactions between the fluorescent 
ligand and the MC4 receptor could be described as a simple one-site binding 
process, whereas at higher Cy3B-NDP-α-MSH concentrations the appearance of 
additional low affinity receptor binding site, that was “invisible” at lower 
fluorescent ligand concentrations, becomes evident. These observations are 
consistent with previously obtained results from MC4 receptor studies with 
radiolabelled [
125
I]-NDP--MSH. The emergence of an additional lower affinity 
MC4 receptor-ligand interaction site with slow association kinetics observed in 
present study supports the previously developed model where ligand binding to 
MC4 receptor is regulated by tandemly arranged ligand binding sites on the MC4 
receptor dimer.  
15
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Figure 8. Association kinetics of 0.5 nM Cy3B-NDP-α-MSH binding to different 
concentrations of the MC4 receptors in the BBV preparation. Two experimental data 
surfaces, one in the presence and one in the absence of excess of non-labelled NDP-α-
MSH, were globally fitted and the lines represent the results of the non-linear 
optimisation procedure. The final concentrations of the MC4 receptor binding sites in 
the wells were posteriorly calculated after global fitting and were presented on the 
receptor concentration axis (1.26, 0.93, 0.69, 0.51, 0.38, 0.28, 0.21, 0.153, 0.113, 0.083, 
0.062 and 0 nM). The distribution of residuals between the experimental data and the 
global fit is presented on the lower panel as the mean of all time courses (×) ± the 
standard deviation (dashed lines).  
 
From the displacement curves obtained in competition binding experiments 
with MC4 receptor specific agonists and antagonists we were able to estimate 
apparent binding affinities   
   
, which are in agreement with the affinities 
found from literature and determined with other methods. However, instead of 
the heterogeneous displacement curves we obtained from radioligand com-
petition experiments (Kopanchuk et al., 2005), relatively homogeneous com-
petition patterns have been observed in the majority of FA-based displacement 
experiments with BBVs. It could be explained by different assay performance 
conditions used. In the FA assays we used a comparable receptor and labelled 
ligand concentrations, and in these conditions ligands compete primarily for the 
high affinity sites; whereas in radioligand competition experiments the 
concentration of radioligand was over 10 times higher than the receptor 
concentration, and ligands are competing for both high and low affinity MC4 
receptor sites.   
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6. CONCLUSIONS 
In summary, the results from biochemical studies of melanocortin receptors 
allowed us to make the following conclusions: 
 Most of the compounds from the library of 210 designed and newly 
synthesised tertiary amides were able to compete with [
125
I]-NDP-α-MSH 
for the binding to melanocortin receptors MC1, MC3, MC4 and MC5 with 
micromolar affinities (Paper I).  
 Seven of the title compounds tested for their ability to promote or block the 
accumulation of cAMP, demonstrated the ability to inhibit the cAMP 
accumulation caused by α-MSH on all studied MC receptor subtypes (Paper 
I). In some cases the inhibition was incomplete as the remained level of 
cAMP was higher than the control level of cAMP. This indicates that tested 
compounds act as MC receptor antagonists and/or partial agonists (no more 
additional studies were performed to clearly distinguish between these two, 
competitive antagonistic and partial agonistic, activities). 
 Membrane preparations from transfected Sf9 cells recombinantly expressing 
corresponding MC receptors are suitable targets for radioligand binding 
studies, improving the quality of the assay (Paper II).  
 Comparative studies of the MC4 receptor with two different radioligands, 
[
125
I]THIQ and [
125
I]-NDP-α-MSH, revealed that ligand binding to this 
receptor is regulated by complex mechanism (Paper II). Differences in 
binding kinetics of these two radioligands were the base for the development 
of model according to which the ligand binding occurs to the tandemly 
arranged interconnecting ligand binding sites on the MC4 receptor dimer. It 
was demonstrated that the complex mechanism of the ligand binding to the 
receptor and different kinetic characteristics of radiolabelled ligands and 
non-labelled competitive ligands may cause the situations where apparent 
binding potency of competitor differs up to four orders of magnitude, 
depending on the radioligand used in the competition binding assay. This in 
turn would lead to the “loss” of potentially perspective compounds in 
radioligand HTS assays.            
 We have implemented the FA method for the comparative characterisation 
of two fluorescent ligands’, Cy3B-NDP--MSH and TAMRA-NDP--
MSH, binding dynamics to the MC4 receptors expressed on the membranes 
from homogenised Sf9 cells (Paper III). The Cy3B-NDP--MSH has been 
found to be more suitable for continuous monitoring of the binding 
reactions, thus enabling characterisation of both labelled and non-labelled 
ligand binding dynamics to the receptor.  
 BBVs that display MC4 receptors on their surfaces were for the first time 
implemented in an FA assay system as a source of GPCRs and found to be 
suitable for investigation of the receptor-ligand interactions (Paper IV).  
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 The inherent properties of the FA method and high assay quality provided by 
BBVs leads the experimental data to a level when the application of global 
data analysis is feasible and reasonable. Global analysis strategy worked out 
for a mathematical description of FA kinetic data with analytical expressions 
allows for the estimation of binding parameters for labelled as well as for 
unlabelled ligands (Paper IV).  
 
All findings pointed out here can be considered as single steps in our progress 
of studies aiming at development of assay systems that would facilitate seeking 
novel MC receptor specific ligands as well as allow for characterisation of 
receptor-ligand interaction mechanisms that would enhance our general 
understanding of the melanocortin system. We believe that our findings and 
developments would also be applicable for other GPCR systems and would 
become a valuable tool for pharmaceutical and academic studies of pharma-
cologically active compounds and GPCRs in general.    
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7. SUMMARY IN ESTONIAN 
Uudsete meetodite arendamine ligandide sidumisomaduste 
uurimiseks melanokortiini 4 retseptorile 
Käesolev doktoritöö käsitleb uuringuid, mille põhieesmärgiks oli uute katse-
süsteemide väljatöötamine, mida saaks kasutada nii melanokortiini retseptorite 
spetsiifiliste ligandide avastamiseks kui ka üldiselt retseptor-ligand vastasmõju 
mehhanismide iseloomustamiseks. Viis melanokortiini (MC) retseptorite ala-
tüüpi (MC1–5) kuuluvad suure raku membraanil asuvate G valguga-seotud 
retseptorite (GPCR) perekonda ning osalevad mitmete oluliste füsioloogiliste 
funktsioonide regulatsioonil nagu pigmentatsioon, seksuaal- ja toitumiskäitu-
mine, energiatasakaalu reguleerimine, valu ja keha temperatuuri reguleerimine, 
immuunsed ja põletikuvastased reaktsioonid, jne. Seega on MC retseptoritele 
spetsiifilised ligandid perspektiivsed ravimikandidaadid selliste haiguste ravi-
miseks nagu rasvumine ja anoreksia, melanoom, erektsiooni ja seksuaalsuse 
häired, aga ka ärevushäired ning depressioon. Uute tõhusate ravimite leidmine 
sõltub suurel määral ka meie teadmistest retseptor-ligand vastasmõju mehha-
nismide kohta ning oskusest kasutada neid teadmisi uudsete efektiivsete ravi-
ainete disainimiseks. Lisaks sellele, oleneb tihti ka meetodist, mis on antud 
juhul meie „silmadeks” selles katsesüsteemis, millist toimeaine mõju me üldse 
näeme ja kui hästi me seda detekteerida ning iseloomustada suudame. Siin töös 
arendatud uudsed fluorestsentsanisotroopial (FA) põhinevad kastesüsteemid 
võimaldavad loobuda radioaktiivsete ühendite kasutamisest ning jälgida 
retseptor-ligand vastasmõjusid reaalajas. See võimaldab saada täiendavat 
informatsiooni organismide melanokortiinse süsteemi funktsioneerimise kohta, 
aga ka luua automatiseeritud katsesüsteem uute aktiivsete ühendite leidmiseks. 
 
Töö üldise eesmärgi saavutamiseks püstitati mitu konkreetset tööülesannet: 
 Uute MC retseptoritele aktiivsete ainete sidumis- ja funktsionaalomaduste 
karakteriseerimine ja võrdlemine 
 Uue radioaktiivse ligandi kasutamine MC4 retseptor-ligand vastasmõju 
mehhanismi karakteriseerimiseks  
 FA meetodil põhineva katsesüsteemi kasutamine MC4 retseptor-ligand 
vastasmõju omaduste karakteriseerimiseks 
 Rakkudest pungunud bakuloviiruste (BBV) kasutamine retseptor allikatena 
FA põhinevas katsesüsteemis MC4 retseptor-ligand vastasmõju omaduste 
karakteriseerimiseks 
 
Kokkuvõtvalt võimaldasid biokeemiliste uuringute tulemused jõuda järgmiste 
järeldusteni: 
 Enamik testitud ühenditest (ühendite raamatukogu koosnes 210 uudselt 
disainitud ja sünteesitud tertsiaarsest amiidist) omasid sidumisaktiivsust MC1, 
MC3, MC4 ja MC5 melanokortiini retseptori alatüüpidele, konkureerides [
125
I]-
NDP-α-MSH seostumisega mikromolaarse afiinsusega (Publikatsioon I). 
16
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 Seitsmest ühendist koosnevat valimit testiti cAMP akumulatsiooni katses ja 
kõik seitse ühendit demonstreerisid võimet inhibeerida α-MSH poolt 
stimuleeritud cAMP akumulatsiooni kõigi uuritud MC retseptori alatüüpide 
korral (Publikatsioon I). Mõnel juhul oli inhibeerimine mittetäielik, kuna 
lõplik cAMP tase jäi kõrgemale kontrolltasemest. Sellest tulenevalt võis 
järeldada, et testitud ühendid käituvad retseptori antagonistidena ja/või 
osaliste agonistidena. 
 In vitro katsetes osutusid membraanpreparaadid, mis olid valmistatud 
rekombinantset retseptorvalku ekspresseerivatest Sf9 rakkudest, oluliselt 
paremateks kui tervete rakkude preparaadid, mistõttu kasutati neid edasistes 
radioligandi sidumise uuringutes (Publikatsioon II). 
 Uurides kahe erineva radioligandi, [125I]THIQ and [125I]-NDP-α-MSH, sidu-
misomadusi MC4 retseptorile, täheldati et nende sidumiskineetika on 
üksteisest väga erinev, aga kummagi ligandi sidumine pole kirjeldatav lihtsa 
biomolekulaarse reaktsioonmudeliga (Publikatsioon II). Mõlemate radio-
ligandi sidumiskineetika komplekssus ja erinevused viisid mudelile, mille 
järgi ligandid saavad seostuda kindlas järjekorras MC4 retseptori dimeeri 
tandemis asetsevatele sidumiskohtadele. Ligandide järjestikune seostumine 
tekitab osaliselt mittekonkurentse olukorra, kus võib juhtuda, et uuritava 
ühendi näiv afiinsus resteptorile võib erineda kuni neli suurusjärku, olenevalt 
väljatõrjumiskatses kasutatava radioligandi omadustest. See võib omakorda 
viia oluliste ravimkandidaatide „kaotuseni“ laiaulatuslikes kiirsõelumis 
katsesüsteemides, kus ligandide kineetikale erilist tähelepanu ei pöörata. 
 Võtsime kasutusse ja arendasime edasi FA põhinevat meetodit ligandide 
sidumise uurimiseks MC4 retseptorile. Leidsime kaks fluorestsentsligandi, 
Cy3B-NDP--MSH ja TAMRA-NDP--MSH, mis võimaldasid jälgida 
ligandi sidumise dünaamikat MC4 retseptorile homogeniseeritud Sf9 rakkude 
membraanides (Publikatsioon III). Seejuures osutus Cy3B-NDP--MSH 
olulisemalt stabiilsemaks, võimaldades uurida nii märgistatud kui 
märgistamata ligandide sidumisdünaamikat mitmete tundide jooksul. 
 Näitasime esmakordselt, et rakkudest pungunud bakuloviirused koos nende 
pinnal olevate MC4 retseptoritega on väga sobiv materjal retseptor-ligand 
vastasmõjude uuringuteks FA katsesüsteemis (Publikatsioon IV). Viirus-
osakesed tagavad retseptorpreparaadi homogeensuse ja ka stabiilsuse lahuses 
väga pika katseaja jooksul. Antud lähenemine ja metoodika on perspektiivne 
ka teiste GPCRide uurimisel ja automatiseeritud kiirsõelumissüsteemide 
arendamisel. 
 FA meetodile iseloomulikud omadused ja BBV poolt tagatud katsesüsteemi 
kõrge kvaliteet on viinud eksperimentaalsed andmed uuele tasemele, kus 
globaalse andmeanalüüsi rakendamine on võimalik ja põhjendatud. Töötati 
välja globaalanalüüsi strateegia FA kineetiliste andmete matemaatiliseks 
kirjeldamiseks, mis võimaldab arvutada kineetilisi sidumisparameetreid nii 
märgistatud kui märgistamata ligandide jaoks (Publikatsioon IV). 
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Käesolevas töös arendatud uudsed fluorestsentsanisotroopial põhinevad kaste-
süsteemid võimaldavad loobuda radioaktiivsete ühendite kasutamisest ning 
jälgida retseptor-ligand vastasmõjusid reaalajas. See võimaldab saada täien-
davat informatsiooni organismide melanokortiinse süsteemi funktsioneerimise 
kohta ning luua automatiseeritud katsesüsteem uute aktiivsete ühendite 
testimiseks. Seejuures usume, et meie arendused on rakendatavad ka teiste 
retseptorsüsteemide uurimiseks ning neist saab oluline vahend nii biokeemiliste 
mehhanismide uuringuteks, kui ka uute farmakoloogiliselt aktiivsete ühendite 
leidmiseks. 
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